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Chronic lung disease is the third leading cause of death in the United States.  Emphysema 
and pulmonary fibrosis are two of the most common forms and are thought in part to 
represent a premature aging phenotype in the lung. This thesis aims to define the role of 
telomeres in the genetics of age-related lung disease.  Using publically available 
sequencing data from patients with severe, early-onset COPD, we identified telomerase 
mutations as a novel Mendelian genetic cause of emphysema.  The patients in this cohort 
showed a unique gene-environment interaction in which smoking was necessary for 
development of the emphysema phenotype, and female telomerase mutation carriers were 
particularly prone to developing emphysema.  In a family with pulmonary fibrosis and 
idiopathic infertility we demonstrated a case of functional reversion in the proband, who 
carried both a germline dominant negative missense allele in the telomere binding protein 
TINF2 and an acquired somatic deletion in cis that abolished expression of the missense 
allele in bone marrow-derived cells.  In the final chapter, we identify mutations in the 
RNA biogenesis protein NAF1 as a cause of autosomal dominant familial pulmonary 
fibrosis-emphysema.  The mutations segregated with the disease phenotype and short 
telomeres and disrupted nuclear targeting of NAF1.  Taken together, these genetic 
findings have immediate clinical implications in the lung transplant setting, as patients 
with short telomeres are especially sensitive to myelosuppresive regimens.  They also 
point to telomere-mediated senescence as a key mechanism of age-related lung disease 
pathogenesis.  
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Recent advances have defined a role for abnormally short telomeres in a broad spectrum 
of genetic disorders.  They include rare conditions such as dyskeratosis congenita as well 
pulmonary fibrosis and emphysema.  Now, there is new evidence that some familial 
cancers, such as melanoma, are caused by mutations that lengthen telomeres.  Here, we 
examine the significance of these short and long telomere length extremes for 




The origins of telomere human genetics  
Telomeres and telomerase were first discovered in Tetrahymena thermophila, a 
protozoan of no obvious clinical significance(1, 2).  Genetic models in yeast, mice, and 
human cells subsequently established a framework for how chromosome ends are 
maintained before disease connections crystallized(3).  Now, abnormally short telomeres 
are appreciated to mediate common age-related disorders such as pulmonary fibrosis and 
emphysema(4).  While the clear connection between short telomeres and degenerative 
disease may have suggested a hypothetical benefit for long telomeres, new discoveries 
have uncovered a potential link between long telomeres and familial cancer syndromes(5-
7).  Here, we review how extreme telomere length abnormalities, both short and long, 
inform understanding the molecular basis of diseases associated with aging as well as 
cancer.  
 
Telomere length is a “molecular clock” mechanism 
Telomere shortening is considered one of the best-characterized mechanisms of cellular 
aging(4).  This claim builds on the fact that telomere length predicts the onset of 
replicative senescence(8, 9).  Telomeres also shorten in humans with age, and in the past 
decade, it has become clear that abnormally short telomeres recapitulate several 
premature aging phenotypes(4).  The progressive shortening of the TTAGGG telomeric 
sequence occurs because DNA polymerases cannot fully copy to chromosome ends(10).  
Telomerase offsets this ‘end replication problem’ by synthesizing new telomere 
sequences(2, 11, 12).  When telomeres become critically short, they activate a DNA 
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damage response(13), which provokes cellular senescence or apoptosis(14-18); these 
responses underlie the progressive disease phenotypes seen in disorders that share the 
short telomere defect as a driving mechanism.   
 
Several safeguards restrict telomere elongation in favor of net shortening with aging.  
They include a tight regulation of telomerase levels, as well as intrinsic factors at 
telomeres that limit excessive elongation by telomerase(19-21).  The expression of the 
reverse transcriptase component of telomerase, TERT, is also repressed in most adult 
tissues.  In hematopoietic as well as other somatic stem cells, even though telomerase is 
expressed, its low levels do not offset the telomere shortening that normally occurs with 
aging(19, 22-24).  As we will discuss here, genetic defects that disturb this telomere 
length homeostasis cause highly penetrant disease phenotypes. 
 
The mammalian short telomere phenotype was first studied in telomerase null mice(14, 
15, 25).  While telomerase loss alone has no clinical consequences in the first generation, 
late-generation telomerase null mice accumulate short telomeres(14, 15, 18, 25, 26).  The 
short telomeres cause degenerative organ failure indicating that the telomere length, and 
not telomerase loss, is the primary determinant of the phenotype.  Late-generation mice 
with short telomeres develop a stem cell failure phenotype, which is prominent in highly 
proliferative tissues such as the bone marrow and intestinal tract where stem cell 
replicative potential is critical for homeostasis(14, 15, 18, 25, 26).  The human short 
telomere syndromes recapitulate these phenotypes(21, 27). 
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THE SHORT TELOMERE SYNDROMES 
The human short telomere phenotype in high turnover tissues 
Studies over the past decade have linked the human short telomere phenotype to a broad 
spectrum of disease(21); it varies in severity and spans the entire age spectrum from 
infancy to adulthood (Figure 1).  While at onset their clinical and histopathologic 
classification alone may show few shared features, a growing appreciation for their 
genetics has highlighted a unified natural history(28).  Their recognition as a single 
syndromic spectrum is critical for treatment decisions, because even though a single 
organ presentation may arise initially, the systemic telomere defect complicates treatment.  
Because some of these complications can be averted, the molecular grouping of disease 
across organs under the short telomere syndrome umbrella exemplifies a molecular 
medicine paradigm that directly advances patient care(27, 29, 30).    
 
The short telomere phenotype in children and young adults represents more severe 
disease(4).  Bone marrow failure is its most common first manifestation, and stem cell 
transplantation alleviates this condition pointing to a stem cell-autonomous defect in this 
compartment(21, 31-34).  Affected individuals are also prone to developing intestinal 
villous atrophy, immunodeficiency and infertility(21, 27, 35).  Pediatric presentations 
may also be recognized in historically defined syndromic entities.  Dyskeratosis 
congenita was the first disorder to be linked to telomerase mutations and short 
telomeres(36, 37); it is classically defined by abnormalities in the skin, mucosa and 
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nails(38, 39).  Hoyeraal-Hreidarsson syndrome manifests in infancy and is characterized 
by developmental delay, enterocolitis, and immunodeficiency(27, 40-42).  The criteria for 
recognizing Hoyeraal-Hreidarsson syndrome and dyskeratosis congenita may be specific; 
but they identify only a small subset of all short telomere syndrome presentations(43).    
 
The slow turnover phenotype in short telomere syndromes 
Lung disease is the most common presentation of short telomere syndromes and it 
represents an attenuated, adult-onset phenotype (Figure 1)(43).  Two types of lung 
disease have been linked to mutant telomerase and telomere genes.  Idiopathic pulmonary 
fibrosis and the related interstitial diseases are marked by progressive lung scarring.  
Familial pulmonary fibrosis is a common manifestation of short telomere syndromes(43), 
and mutant telomere genes explain one third of all cases(44-49).  Telomerase mutations 
have also been recently linked to the risk of emphysema(50).  The frequency of 
telomerase mutations in severe emphysema rivals alpha-1 antitrypsin deficiency, which 
until recently was its only known Mendelian cause(50).  In families with telomerase 
mutations, emphysema appears in smokers, while pulmonary fibrosis is the predominant 
pathology in never smokers(50).  This apparent phenotypic heterogeneity points to a 
profound gene-environment interaction in a Mendelian disorder in which a single 
mutation causing telomere shortening provokes fibrotic scarring in never smokers and 
emphysematous airspace destruction in smokers(50).  In animal models, telomere 
dysfunction in alveolar stem cells triggers cellular senescence and recapitulates many 
features of the human lung pathology including recruitment of an inflammatory 
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response(51).  The fibrosis-emphysema caused by short telomeres may therefore also 
result from stem cell failure, and this biology points to potential new approaches to their 
treatment(4, 51).  Pulmonary fibrosis and emphysema are estimated to affect 100,000 and 
5 million individuals, respectively, in the United States alone(52, 53). Their disease 
burden, along with their close association with telomere genetics, makes the short 
telomere syndromes the most prevalent among the premature aging disorders. 
 
Cancer in the short telomere syndromes 
Although the majority of the premature mortality in the short telomere syndromes is 
caused by degenerative organ failure, there is also an increased risk for cancer.  Cancer is 
estimated to affect 10% of dyskeratosis congenita cases, and when it arises, it is 
diagnosed at a younger age than the general population(54).  The basis of the cancer 
prone state in the short telomere syndromes is not understood, but its predilection appears 
to be for high turnover tissues where stem cell failure also occurs.  Short telomere 
syndromes are associated with an increased incidence of non-melanoma skin cancers, as 
well as squamous cell carcinomas of the head and neck(54), but the highest risk is for 
myelodysplasia and acute myeloid leukemia.  These latter bone marrow-derived 
malignancies are often a first manifestation of telomere-mediated disease(54, 55).  In the 
bone marrow, the stem cell failure state and progressive stem cell dropout may cause 
replication errors in surviving stem cells that could lead to a clonal advantage.  Short 
telomere patients may also have impaired cancer surveillance because of 
immunosenescence(21).  All in all, even though the rate of some types of cancers in short 
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telomere syndromes is higher than in the general population, its overall incidence is 
dwarfed by organ failure which accounts for 90% of the mortality(38).   
 
The genetics of short telomere syndromes 
Short telomere syndromes show Mendelian inheritance, and as of this writing, 11 genes 
have been identified(34, 36, 48, 56-67) (Figure 2).  Together, they explain 50-70% of the 
short telomere Mendelian phenotype.  Mutations in these genes disturb telomere 
homeostasis by impairing telomerase biogenesis, affecting its catalytic functions, its 
recruitment by shelterin, or the stability of telomere replication machinery components 
(Figure 2).  The predominant phenotype and age of onset do not depend on the gene or 
the mutation type, but is determined by the extent by which a given mutation causes 
telomere shortening(68).  The most prevalent cause of short telomere syndromes is 
heterozygous loss-of-function mutations in TERT, which manifest in adults as autosomal 
dominant familial pulmonary fibrosis(4) (Figure 3A).  In rare cases, biallelic TERT 
mutations have also been described and they are associated with more severe short 
telomere defects and early-onset disease(69).  Mutations in RTEL1 and PARN also show 
a similar pattern of adult- and pediatric-onset disease depending on whether one or two 
alleles are affected, respectively(48, 63, 70).   
 
Genetic anticipation and the evolving disease pattern in the telomere syndromes 
Two features distinguish the genetics of autosomal dominant short telomere syndromes 
from other Mendelian disorders; and they explain the natural history of these disorders.  
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The first is that autosomal dominant families with short telomere syndromes show 
genetic anticipation, an earlier and more severe onset of disease in each successive 
generations(57, 71) (Figure 3A).  Telomere shortening is a second established molecular 
mechanism for genetic anticipation in addition to trinucleotide repeat expansion.   The 
successive telomere shortening eventually precipitates severe pediatric disease and/or 
infertility, leading to loss of the mutation in that lineage(46, 68).  Telomere gene 
mutations thus tend to be private to each autosomal dominant kindred, leading to 
significant allele heterogeneity.  In addition to the earlier onset in later generations, the 
disease evolves from slow-turnover tissues in older generations (e.g. pulmonary fibrosis-
emphysema) to a high-turnover phenotype in younger generations (e.g. bone marrow 
failure)(68).  The rate of genetic anticipation and disease evolution within a family 
depends on the extent of telomere shortening caused by a given mutant allele across a 
generation(72).  As we will highlight below, cancer prone families with mutations that 
may conversely promote telomere lengthening also show evidence of genetic anticipation.   
 
THE LONG TELOMERE SYNDROMES 
The price of long telomeres in an increased risk of melanoma 
The premature aging phenotypes caused by abnormally short telomeres may intuitively 
suggest that long telomeres confer an advantage for health and lifespan.  However, there 
is increasing evidence that such a view may be overly simplistic.  In the past two years, 
mutations that appear to lengthen telomeres have been linked to an increased risk of 
cancer.  It is these familial cancer syndromes that we posit here are long telomere 
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syndromes (Figures 1.1 and 1.3).  They are also caused by mutations in telomerase and 
shelterin genes and two of these genes have been implicated also in the short telomere 
syndromes (Figure 1.2).  The cancer spectrum in these putative long telomere syndromes 
is not yet fully defined, but so far it appears to be particularly enriched for melanoma and 
glioma(5-7, 73, 74).  Notably, these cancers are different from the squamous cell and 
hematologic malignancies that arise in the short telomere syndromes.   
 
Mutations in telomere genes that cause familial cancers  
Evidence that mutant genes that may promote telomere lengthening cause familial cancer 
came first from a large melanoma kindred that carried an activating mutation in the TERT 
promoter(5).  This mutation creates an E-twenty-six (ETS) binding site that turns on 
TERT transcription(5, 75, 76).  Such a mechanism contrasts with the TERT loss-of-
function mutations seen in the short telomere syndromes that impair the enzyme’s 
catalytic functions(57) (Figure 3A).  Somatic TERT promoter mutations are also found in 
70% of melanomas(75) as well as a number of other solid tumors(77).  Their high 
prevalence makes TERT promoter mutations some of the most common somatic 
mutations seen in human cancer and points to telomerase abundance as critical in cancer 
initiation and progression.   
 
Since the initial description of a TERT promoter mutation in a family with melanoma, 
germline mutations in three other telomere gene, all encoding shelterin components, have 
been linked to familial melanoma and glioma(6, 7, 73, 74) (Figure 2).  They include 
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POT1, TPP1 and RAP1(6, 7) (Figure 2).  Like TERT, mutations in TPP1 can cause both 
short and long telomere syndromes.  TPP1 is a shelterin component that has been 
implicated in telomerase recruitment, but it also functions to prevent telomerase access to 
the telomere(78-80).  Its dual functions explain the contrasting net effect of TPP1 
mutations on telomere length.  The single TPP1 mutation identified in short telomere 
syndromes is missing a single amino acid in the TEL patch domain; this impairs 
telomerase recruitment resulting in net shortening(61, 62).  The resulting disease 
phenotype is marked by stem cell failure and a small increased cancer risk.  In contrast, 
TPP1 nonsense mutations in cancer prone families disrupt protein stability, and are 
predicted to allow improved telomerase access and promote telomere elongation(62, 73, 
80).  Based on the genetic anticipation documented for short telomere syndromes, it 
would be expected that long telomere length may similarly be expected to be inherited 
across generations(18, 26, 57, 81).  A close examination of the published pedigrees 
interestingly shows a pattern of genetic anticipation for the age of melanoma-related 
diagnosis and mortality(6, 7, 73).  While it is theoretically possible that lead time bias (i.e. 
the earlier detection of cancers because of earlier screening) could explain this pattern, 
the fact that this genetic anticipation occurs for the age at death as well as diagnosis 
favors a model where progressively longer telomeres promote and earlier onset and a 
more aggressive cancer course in later generations (Figure 3B).   
 
How would abnormally long telomeres predispose to melanoma?  
Studies over the past two decades in animal models shed light on how long telomeres 
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may promote cancer-related mortality.  Although mice with short telomeres show limited 
survival because of their stem cell failure phenotypes, in cancer prone contexts they show 
a paradoxical advantage in overall survival(82-85).  This benefit has been reproduced 
across cancer prone models, including oncogene-driven cancers, such as Myc and K-ras, 
as well as those driven by loss of tumor suppressors such as Apc and Ink4a(82-85).   The 
survival advantage is seen despite the fact that short telomere mice accumulate more 
micro-tumors, because short telomeres induce the apoptosis and senescence checkpoints 
in these pre-cancers(83, 86).  Thus, short telomeres confer an overall benefit at the 
organismal level in animal models where cancer is genetically induced by a single 
driving mutation.  
 
The evidence from population studies also supports an association between long 
telomeres and the risk for some cancers and is best documented for malignant 
melanoma(87-90), an intriguing observation in light of the cutaneous melanoma-rich 
phenotype documented in the long telomere syndromes.  Cutaneous malignant melanoma 
is marked by some of the highest mutation burdens among human cancers because of the 
mutagenic effects of ultraviolet light(91).  Its clustering in families and individuals who 
have long telomeres underscores an important role for the telomere-mediated replicative 
senescence checkpoint in suppressing tumors where mutagenesis is environmentally 
induced.  Unrestricted proliferation when telomeres are long would increase the 
likelihood of sustaining driver mutations that eventually promote a clonal advantage and 
metastasis.  The role of long telomeres in promoting cancer is however complex and the 
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association between long telomeres and cancer risk may be tissue specific. For example, 
non-melanoma types of skin cancer, such as squamous cell carcinoma have been 
paradoxically associated with short telomeres(92).  The available evidence thus suggests 
that distinct cancer phenotypes are associated with both short and long telomere 
syndrome extremes, and that a melanoma-rich phenotype will be a hallmark of long 
telomere syndromes. 
 
SUMMARY AND LOOKING AHEAD 
Emerging discoveries have painted a rich mosaic of how telomere length abnormalities at 
the extremes play a role in disease.  The short telomere syndromes unite a group of stem 
cell failure disorders that share a single molecular pathology.  Their grouping informs 
treatment and pathogenesis paradigms for common and poorly understood conditions 
especially lung disease.  The short telomere phenotype overlaps with disease phenotypes 
that are normally acquired with aging, and it is associated with a modest cancer risk.  At 
the other extreme, the long telomere syndromes manifest as a highly penetrant cancer 
predisposition.  They are enriched for cutaneous melanoma presumably because in the 
setting of environmentally induced mutagenesis, the loss of the replicative senescence 
checkpoint promotes carcinogenesis. Both disease extremes point to the importance of a 
telomere length equilibrium in maintaining stem cell homeostasis with aging while 
simultaneously minimizing cancer risk. 
 
The profound disease phenotypes caused by extreme telomere length disturbances raise 
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the possibility that targeting telomere length may be a plausible therapy strategy.   In the 
short telomere syndromes, replenishing defective stem cells, such as is currently done 
with bone marrow transplantation, or aiming to elongate telomeres, could be clinically 
beneficial.  In contrast, for long telomere-associated cancers, inhibiting telomerase could 
be effective in preventing or treating cancer.  How much leeway is available to exploit 
this delicate system therapeutically remains to be determined, and any treatment approach 




Figure 1.  Telomere length extremes and their predominant clinical manifestations.  
Telogram showing the decreasing telomere length range across the age spectrum with percentile 
lines defining the normal range at every age.  The short telomere syndromes have typical 
manifestations that are represented by the red circles at the typical age range of onset.  Familial 
melanoma and glioma have been linked to mutations that putatively cause long telomeres.  The 
typical presentations and age of onset for each of the presentation is also indicated.   
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Figure 2.  Telomerase and telomere components that cause short and long telomere 
syndromes.  These mutations affect telomerase catalytic activity or processivity (TERT and TR), 
telomerase biogenesis (dyskerin encoded by DKC1), NOP10 and NHP2, or its trafficking 
(TCAB1 also known as WRAP53).  Mutations in short telomere syndromes also affect shelterin 
components TIN2 (encoded by TINF2), TPP1 (encoded by ACD), POT1 and RAP1 (encoded by 
TERF2IP).  CTC1 and RTEL1 affect lagging strand synthesis and telomere replication, 
respectively.  PARN is involved in RNA processing and deadenlyation; its function in telomere 
maintenance has not been fully characterized.  The ‘S’ subscript indicates a link to short telomere 
syndromes (n=11 genes), while the ‘L’ superscript indicates a link to long telomere syndromes 
(n=4 genes).  Mutant components are shown in color and gray denotes telomere components not 













Figure 3.  Genetic anticipation in the autosomal dominant short and long telomere 
syndromes.  A. In the short telomere syndromes, successive telomere shortening across 
generations manifests in disease that shows an earlier age of onset.  There is also an evolving 
pattern with ancestors developing lung disease and their progeny having a higher incidence of 
high turnover phenotypes such as bone marrow failure.  B. Long telomere syndromes appear to 
also show genetic anticipation of the melanoma phenotype; this is caused by inheritance of long 
telomeres (right panel).  Mutations in TERT have been linked to both syndromes with short 
telomere syndromes being caused by loss-of-function mutations (left), while familial melanoma is 
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Mutations in the essential telomerase genes, TERT and TR, cause familial pulmonary 
fibrosis; however, in telomerase null mice, short telomeres predispose to emphysema 
after chronic cigarette smoke exposure.  Here, we tested whether telomerase mutations 
are a risk factor for human emphysema by examining their frequency in smokers with 
chronic obstructive pulmonary disease (COPD).  Across two independent cohorts, we 
found 3 of 292 severe COPD cases carried deleterious mutations in TERT (1%).  This 
prevalence is comparable to the frequency of alpha-1 antitrypsin deficiency documented 
in this population.  The TERT mutations significantly compromised telomerase catalytic 
activity and mutation carriers had short telomeres.   Telomerase mutation carriers with 
emphysema were predominantly female, and had an increased incidence of 
pneumothorax.  In families, emphysema showed an autosomal dominant inheritance 
pattern, along with pulmonary fibrosis and other telomere syndrome features, but 
manifested only in smokers.  Our findings identify germline mutations in telomerase as a 
Mendelian risk factor for COPD susceptibility that clusters in autosomal dominant 






Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the 
United States(1).  Aside from cigarette smoke, age is its major risk factor.  However, only 
a subset of smokers, approximately 10%, develops COPD, and the clustering of 
emphysema in families has suggested that genetic factors explain a significant portion of 
this susceptibility(2).  Alpha-1 antitrypsin deficiency is the known Mendelian cause for 
emphysema(2).  It manifests autosomal recessive inheritance because of biallelic 
mutations in the SERPINA1 gene, and accounts young-onset, severe COPD in 0.5-1% of 
smokers of European descent(3).  The other monogenic factors that underlie COPD 
susceptibility are not fully known(2, 4). 
 
Telomeres are the DNA-protein structures that protect chromosome ends.  Telomeres 
shorten with cell division and advancing age, and short dysfunctional telomeres signal a 
DNA damage response that provokes cellular senescence and apoptosis(5, 6).  
Telomerase is the specialized polymerase that synthesizes new telomere repeats(7-9).  It 
has two core components: TERT, the telomerase reverse transcriptase, and TR, the 
telomerase RNA, that provides the template for telomere repeat addition(9, 10).  
Mutations in TERT and TR cause telomerase haploinsufficiency and the consequent short 
telomere defect is most frequently recognized in clinical settings as autosomal dominant 
pulmonary fibrosis(6).  Even though lung disease is the primary life-threatening 
presentation in these patients, the telomere defect is systemic, and can manifest 
concurrently in a predictable, syndromic pattern that includes bone marrow failure, liver 
disease, and osteoporosis(11, 12).  Because extrapulmonary telomere-mediated disease 
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can cause significant morbidity, recognizing this subset of pulmonary fibrosis patients 
has been shown to be relevant for treatment decisions in several settings(6, 12, 13). 
 
We recently sought to understand the mechanisms by which telomere dysfunction causes 
pulmonary fibrosis by studying telomerase null mice with short telomeres.  Although 
these mice have no obvious de novo lung defects, they surprisingly develop emphysema 
after chronic cigarette smoke exposure(14).  Coincident with these findings, we identified 
a family with a deleterious TR mutation that included two female siblings who developed 
premature emphysema, and emphysema combined with fibrosis, after modest smoking 
histories(14).  Another family was recently reported that had a similar clustering of 
emphysema with fibrosis in association with a TERT mutation(15).  The observations in 
mice, in light of these anecdotal cases, led us to systematically test the hypothesis that 
mutations in telomerase may be a risk factor for emphysema in unselected populations.  
Using a candidate gene approach, in two cohorts of smokers with severe 
emphysema/COPD, along with pedigree data from a Johns Hopkins-based study, we 
show that deleterious telomerase mutations are a risk factor for COPD, and may occur at 




Rare TERT variants cluster with the COPD phenotype in two independent cohorts  
To test whether telomerase mutations are a risk factor for emphysema, we examined the 
telomerase gene sequences in exome data from the COPDGene cohort, a study designed 
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to understand the genetic determinants of COPD susceptibility.  These data have been 
recently made accessible through the National Heart Lung and Blood Institute (NHLBI) 
Exome Sequencing Project (Lung GO)(16).  The clinical characteristics of the control 
group (n=206) and emphysema subjects (n=209) are summarized in Table 1.  We 
designed a filtering strategy to identify novel or rare variants that could then be 
functionally examined (Supplementary Figure 1).  In the control group, one rare TERT 
variant, Arg653Cys, was identified; however, this missense substitution did not affect 
telomerase catalytic activity (97 + 5% of wild-type telomerase activity + s.e.m, P=0.49, 
Student’s t-test, Supplementary Figure 2).  In contrast, among the smokers with 
emphysema, there were two heterozygous missense variants in TERT: Arg599Gln and 
Thr726Met (2 of 209, 1%) that we subsequently found to be functionally deleterious as 
shown below.  The Arg599Gln variant was novel, and Thr726Met was previously 
reported in a child with bone marrow failure(17).  We obtained archived DNA from the 
COPDGene parent study and confirmed the presence of these TERT variants by Sanger 
sequencing (Figure 1A).   
 
We next tested the frequency of telomerase mutations in a second cohort of smokers with 
severe COPD.  We queried cases from the Lung Health Study that we selected to match 
the age and forced expiratory volume in 1 second (FEV1) criteria used in the COPDGene 
exome sequencing study, and examined the TERT and TR sequences along with the 
severe alpha-1 antitrypsin deficiency SERPINA1 alleles (Table 1).   Among 83 cases that 
fulfilled these prespecified criteria, we found no homozygous SERPINA1 mutations, but 
we identified an individual with a heterozygous missense TERT mutation: His925Gln 
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(Figure 1A).  This mutation was previously reported in several members of a family with 
pulmonary fibrosis and liver disease(18).  In total, across the two COPD cohorts, there 
were three TERT variants among the severe COPD cases (3 of 292, 1%), and all of them 
fell in conserved motifs within the telomerase reverse transcriptase domain 
(Supplementary Figure 2.3).  The TERT gene contains few deviations from reference 
sequence(19, 20), and none of these variants were found in 2,020 controls including 
1,092 from the 1000 Genome Project, 528 published controls(20), and 400 individuals of 
similar European ancestry who we additionally sequenced (Supplementary Table 1).  
These data suggested a clustering of rare telomerase variants in smokers with severe 
emphysema. 
 
TERT variants compromise telomerase function and telomere length 
To test the functional significance of the rare variants identified, we reconstituted each of 
the TERTs in cells.  We measured telomerase enzyme activity by quantifying the 
telomere products using the direct primer-extension assay.  The three emphysema-
associated TERT variants substantially compromised enzyme activity compared to wild-
type telomerase as evidenced by the decreased intensity of the telomere repeat ladder 
(P<0.001, Student’s t-test, Figure 1B-C).  The reduction in activity was similar to 
pathogenic TERT and TR mutations documented in pulmonary fibrosis(12, 21).  In 
contrast, the enzyme activity of the TERT variant from the control group was comparable 
to wild-type (Supplementary Figure 2).  These data indicated that the clinical phenotype 
of severe emphysema enriched for individuals with rare, deleterious TERT mutations and 
that this clustering was statistically significant [3 of 292 COPD subjects (1%) vs. 0 of 
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2,226 controls (2,020 healthy controls and 206 control smokers), P=0.002, Fisher’s exact 
test].   
 
We examined the functional impact of the variants in vivo by measuring the telomere 
length.  In two deceased subjects we measured telomere length using archived DNA by 
quantitative PCR, and found it was short relative to age-matched healthy controls 
(P=0.018, Student’s t-test, Figure 1E), and comparable to TERT and TR mutation carriers 
with idiopathic pulmonary fibrosis (P=0.66).  Telomere length in the telomerase-
associated emphysema cases was also short compared to the control with the functionally 
intact TERT variant as well as the SERPINA1 mutation carrier with alpha-1 antitrypsin 
deficiency in COPDGene (Figure 1E).  We additionally measured lymphocyte telomere 
length by flow cytometry and fluorescence in situ hybridization (FISH) in the one living 
subject we could contact, and found it fell near the 10th age-adjusted percentile, similar to 
mutation carriers with idiopathic pulmonary fibrosis that were also included in the 
quantitative PCR telomere length analysis (Figure 1C).  These data supported the 
emphysema-associated TERT variants being functionally deleterious. 
 
Telomerase mutations may be associated with a more severe emphysema phenotype 
We examined the clinical data available from COPDGene and the Lung Health Study 
records and found all three mutation carriers were female with a mean age of 48 years at 
diagnosis (Supplementary Table 2).  Chest CT scans in the COPDGene subjects showed 
apical airspace destruction, and one subject had additional interstitial lung abnormalities 
and bronchiectasis (Figure 2A-D).  The dyspnea was severe requiring supplemental 
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oxygen support, and one subject died within five years of enrollment (Supplementary 
Table 2).  Lung Health Study subjects had spirometry documented over five years, and, 
in the subject with the TERT His925Gln mutation, lung function declined faster than the 
lowest quartile of this 5,887 person cohort of smokers suggesting an accelerated disease 
course(22) (Figure 2E).  Family history was not detailed in available study records, but 
we subsequently found the only living subject reported her mother, a smoker, was 
oxygen-dependent for the diagnosis of COPD.   
 
Female gender is a risk factor for telomerase-associated emphysema 
Mutations in telomerase and short telomeres are a risk factor for pulmonary fibrosis(19), 
and we sought to understand the predictors of emphysema onset compared to fibrosis.  
We examined the clinical histories of 50 telomere syndrome cases with lung disease that 
were consecutively recruited as part of a Johns Hopkins-based study (Table 2).  Among 
never smokers, there were no cases of emphysema (0 of 39, 0%).  However, among 11 
smokers, we identified seven emphysema cases (64%).  Notably, the emphysema cases 
were predominantly female with all the female smokers (6 of 6, 100%) developing either 
emphysema alone (n=2) or combined with fibrosis (n=4).  In contrast, only 1 in 5 male 
smokers had radiographic evidence of emphysema (P=0.015, Fisher’s exact test for 
enrichment of the emphysema phenotype in female smokers).  These data suggested that 
short telomeres mediate a unique genetic-environmental interaction that predisposes to 




We analyzed the clinical features of telomere-associated emphysema phenotype by 
combining the Johns Hopkins cases with those we identified in the COPD cohorts (Table 
3).  In aggregate, 9 of the 10 cases were female.  The average smoking history was 30 
pack-years (range, 15-48), and of those that died, the mean age at the time of death from 
lung disease was 62 years (range, 46-68, n=7, Table 3).  Notably, 3 of 9 subjects had 
spontaneous pneumothorax (33%), a rare, life-threatening complication of COPD that 
normally affects 5% of cases(23).  Relative to historic estimates, the likelihood of 
recurrent spontaneous pneumothorax in this genetically uniform subset occurring by 
chance alone is low (P=0.016, Fisher’s exact test).   These clinical observations, albeit in 
a relatively small number, suggested that the telomere-associated COPD phenotype is 
associated with an increased risk for spontaneous air leaks. 
 
Emphysema shows autosomal dominant inheritance with pulmonary fibrosis  
We examined the pattern of inheritance in the five pedigrees of the Johns Hopkins 
emphysema cases.  Four families carried known deleterious mutations in telomerase(12, 
14, 21), including our originally reported family with the mutant TR, and one had classic 
features of a telomere syndrome(11).  The emphysema phenotype in these pedigrees 
showed an autosomal dominant inheritance pattern with pulmonary fibrosis and other 
telomere phenotypes including bone marrow failure and liver disease (Figure 3A).  The 
severity of the telomere defect did not predict the lung disease phenotype as both 
emphysema and fibrosis patients had equally abnormal short telomeres (Figure 3B).  
Notably, even within a single family that shared a telomerase mutation, emphysema 
appeared in female smokers showing an apical distribution, while female non-smokers 
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developed pulmonary fibrosis (Figure 3A-3C).  These data indicated that telomere-
mediated emphysema manifests as autosomal dominant trait, along with pulmonary 
fibrosis, but only appears in smokers. 
 
Discussion 
We report here germline mutations in telomerase are a risk factor for severe emphysema 
in smokers.  Because telomere dysfunction lowers the threshold to emphysema in animal 
models, we tested whether telomerase mutations predispose to human emphysema, and 
found, in two independent cohorts, 1% of cases carried deleterious mutations in TERT.  
This frequency, although it constitutes a relatively small subset, is similar to that reported 
for alpha-1 antitrypsin deficiency in matched COPD populations(3).  The emphysema-
associated TERT variants compromised telomerase catalytic activity, and mutation 
carriers had abnormally short telomeres.  Although a family history for pulmonary 
fibrosis was not detailed in the COPD cohorts we studied, in the families we fully 
characterized, emphysema showed autosomal dominant inheritance with pulmonary 
fibrosis and other telomere phenotypes.  The familial clustering of emphysema with 
fibrosis suggests that these two lung phenotypes, heretofore considered distinct 
pathologies, may in some cases represent a continuum of degenerative lung disease that 
shares telomere dysfunction as a genetic susceptibility.  For emphysema in contrast to 
fibrosis, the cigarette smoke exposure is a necessary second hit.   
 
The evidence we document in human emphysema is compelling because short telomeres 
are a determinant of emphysema susceptibility in telomerase null mice(14).  In these 
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animals, short telomeres lower the threshold to damage caused by cigarette smoke in 
epithelial cells(14).  The additive damage of these ‘two hits’ provokes a DNA damage 
response that causes epithelial senescence(6, 14). Senescence and the resultant loss of 
regenerative capacity may thus be critical events that drive the airspace destruction in 
telomere-mediated emphysema (Alder and Armanios, unpublished).  Telomere length is 
normal in emphysema patients with alpha-1 antitrypsin deficiency(24).  Our data, in light 
of these observations, indicate telomere dysfunction may be a second, independent 
mechanism of emphysema susceptibility that is distinct from protease imbalance 
delineated in alpha-1 antitrypsin deficiency.   
 
Several pieces of evidence suggest that short telomeres may play a broader role in 
emphysema susceptibility beyond the small subset of cases we identified.  First, the 
coverage for TERT in COPDGene included only 75% of the coding sequence similar to 
what has been seen previously(25).  Moreover, in addition to TERT and TR, a number of 
other telomerase and telomere genes have been implicated in the monogenic telomere 
disorders(26, 27).  It is therefore possible that although the telomerase genes may account 
for a small subset, other mutant telomere pathway genes will collectively explain a larger 
proportion of susceptibility.  Even when telomerase is wild-type, telomere length is 
genetically determined and short telomeres are is sufficient to predispose to degenerative 
disease in the lung and elsewhere(28, 29).  The prevalence of telomerase and telomere 




Our findings are significant for patient care because individuals with telomerase  
mutations are at risk for recurrent syndromic features including liver disease, 
osteoporosis and certain malignancies(6).  Some of these same telomere syndrome 
morbidities are known to occur at higher frequency in patients with severe 
emphysema(30).  Our data suggest the inherited telomere defect may play a role in 
simultaneously predisposing to these systemic comorbidities along with the lung disease.  
A telomere-mediated sub-phenotype of COPD may thus require individualized clinical 
care algorithms.  Identifying telomere syndrome patients at the bedside is particularly 
important in the setting of lung transplant since some of these patients may be at 
increased risk for serious toxicities of immunosuppressive medications because of limited 
reserves in the bone marrow, gastrointestinal tract and elsewhere(13).  Relatives of 
telomerase mutation carriers may also be at risk for telomere syndrome complications 
which may occur at an earlier age in successive generations because of genetic 
anticipation(12).  Given the public health burden of COPD, our report suggests that 
emphysema may be a recurrent manifestation of telomere syndromes in populations 

















COPDGene Study.  We accessed the Database of Genotypes and Phenotypes (dbGaP) on 
March 1, 2013 after approval from the Johns Hopkins Medicine Institutional Review 
Board and the National Heart Lung and Blood Institute (NHLBI) Data Access 
Committee.  We analyzed the dbGaP clinical and exome data for the COPDGene 
study(31), and examined the TERT, TR and the SERPINA1 gene sequence 
(phs000179.v3.p2 and pht002239.v2.p2.c1).  Supplementary Figure 2 summarizes the 
depth of coverage for the coding and exon-flanking sequences of the candidate genes.   
 
The COPDGene subjects who underwent exome sequencing (total n=415) were smokers 
who were selected for extreme phenotypes(32).  Case subjects were selected to enrich for 
a severe, early-onset phenotype: younger than 63 years, with severe or very severe 
obstruction [forced expiratory volume in 1 second (FEV1) less than 50% of predicted 
values], and had greater than 15% emphysema on CT scan (n=209)(32).  Controls were 
older than 65 years, had FEV1 greater than 80%, and less than 5% emphysema on CT 
(n=206).  Quantitative chest CT scan assessment was based on the percentage of the lung 
with low attenuation areas below -950 Hounsfield units.  Although subjects with known 
severe alpha-1 antitrypsin deficiency were excluded from COPDGene based on protein 
phenotyping, one PI*ZZ subject was inadvertently included.  To verify exome variant 
calls, we obtained and sequenced archived DNA from the COPDGene investigators after 
ancillary study approval.   
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Lung Health Study.  To test the hypothesis in a second cohort, we selected Lung Health 
Study subjects who fulfilled similar criteria to COPDGene for candidate gene 
sequencing.  Smokers had FEV1<50% of predicted values and were younger than 65 
years (n=83).  Lung Health Study participants had mild or moderate obstruction at the 
time of study entry, so we used selection criteria to identify subjects who developed 
severe obstruction at five years, the last timepoint pulmonary function was documented.   
 
Johns Hopkins Registry.  Families were recruited through the Johns Hopkins Telomere 
Syndrome Registry from July 1, 2005 to June 30, 2014.  The study aims at understanding 
the genetics and natural history of telomere-mediated disease(33).  The study was 
approved by the Johns Hopkins Medicine Institutional Review Board, and all the subjects 
gave written informed consent.  Lung disease type was assessed for each of the subjects 
by CT imaging and review of the medical records including pulmonary function studies 
and death certificates.  Chest CT images were available for review in 90% of the subjects, 
and, in the remaining cases, chest X-Ray and death certificate information were 
ascertained to determine the diagnosis. 
 
Exome sequence analysis.  Sequence files were annotated using publicly available  
software(34).  Variants were selected for functional analysis if they had been absent in 
1000 Genomes(35) as well as dbSNP build 130 (http://www.ncbi.nlm.nih.gov/SNP/), an 
uncontaminated earlier version of variants, and additionally had less than 0.001 minor 
allele frequency in the Exome Variant Server Database 
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(http://evs.gs.washington.edu/EVS).  Candidate variants that fulfilled our filtering criteria 
from the exome data were confirmed by Sanger sequencing as previously described(21).  
We also manually sequenced TR in COPDGene subjects by PCR because of low 
coverage(21) (Supplementary Figure 4).  The a priori designed filtering strategy is 
summarized in Supplementary Figure 1. 
 
Targeted sequencing.  To screen for telomerase mutations in Lung Health Study 
subjects, we designed and validated a TruSeq Custom Amplicon probe set (Illumina) that 
included the coding and flanking sequences of TERT, TR as well as exon 6 of SERPINA1 
containing the PI*Z allele that is mutated in more than 90% of alpha-1 antitrypsin 
deficiency cases(3).  Libraries were generated from 250 ng DNA and analyzed on a 
MiSeq sequencer (Illumina).  Of 83 samples sequenced, 7 samples (8%) had suboptimal 
coverage (less than 50% at 8X depth); the coverage for the 76 samples that passed quality 
control is summarized in Supplementary Figure 3.  Supplementary Table 3 lists common 
TERT variants found in the COPDGene and Lung Health Study subjects. 
 
Telomere length measurement.  Telomere length was measured on peripheral blood 
lymphocytes by flow cytometry and FISH as previously outlined(21).  In deceased 
subjects, telomere length was measured using archived DNA by quantitative PCR(36).  
For these studies, control and COPDGene genomic DNA was extracted from whole 
blood using the Gentra Puregene method (Qiagen).  Each run included three replicates, 
and the mean from three independent runs was calculated.   
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Telomerase activity assay.  The functional consequences of all the rare variants from the 
COPDGene and Lung Health Studies were examined using the direct telomerase activity 
assay.  Wild-type and variant telomerases were reconstituted in vivo using 293FT cells 
(Invitrogen, Carlsbad, CA) by transient transfection with pcDNA-3xFLAG-hTERT and 
pBS-U1-hTR(37).  The reconstituted telomerase was then immuno-purified from cell 
lysates and analyzed by the direct primer-extension assay at physiologic nucleotide 
concentrations as previously validated and described(29, 37).  The 10 µL direct primer-
extension reaction contained 5 µM dTTP, 5 µM dATP, 5 µM dGTP, 0.165 µM α-32P-
dGTP (3000 Ci/mmol, 10 mCi/mL, Perkin Elmer) and 1 µM (TTAGGG)3 DNA primer in 
1X telomerase reaction buffer (50 mM Tris-HCl pH 8.3, 2 mM DTT, 0.5 mM MgCl2 and 
1 mM spermidine).  Comparable wild-type and mutant telomerase expression in 
transfected 293FT cells (Invitrogen) was confirmed by western blot for the FLAG-tagged 
TERT protein (anti-FLAG, clone M2, Sigma-Aldrich) and GAPDH (clone 6C5, Ambion)  
as an internal control(38).  Comparable immuno-purification efficiency of telomerase 
was also confirmed by northern blot of TR extracted from immuno-purified 
telomerase(39).  Telomerase activity was determined by measuring the total intensity of 
telomerase-generated products on the gel and normalizing against the internal loading 
control (32P end-labeled 18-mer oligonucleotide) and the TR level measured by northern 
blot from immuno-purified telomerase(39).  Quantification was based on four activity 




We used GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego 
California USA, www.graphpad.com.  A two-sided P-value of <0.05 was considered 
statistically significant, and all the P-values shown are two-sided. 
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FEV1, Forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease 
(a scale used to measure chronic obstructive lung disease severity) 
                          
*Smoking status and GOLD stage are from year 5 data for the Lung Health Study subjects 
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               *Subjects are included from 31 families (TERT, n=15; TR n=6, other telomere gene mutation n=5,  
               clinical telomere syndrome or dyskeratosis congenita n=5)  
              
              **P=0.015 for proportion of female smokers with emphysematous changes relative to males                         
             (Fisher’s exact test, two-sided). 
 
  
   Male                         Female 
Number of subjects 
 
    25                                25 
Age at diagnosis (y)    53.1                            54.2  (32-77)                        (34-68) 
Smoking status 
  Never smoker 
  Smokers 
      
20                 19 
 5                                6 
Lung disease relative to smoking history 
  Smokers with emphysema 
  Smokers with fibrosis 
  Never smokers with emphysema 
  Never smokers with pulmonary fibrosis 
         
        1                               6**        
        4                               0        
        0                               0 
       20                             19   
Smoking history (pack-years)      24                               30   (10-41)                      (25-37) 
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Table 3.  Clinical characteristics of telomerase mutation carriers with emphysema alone or 
combined with fibrosis (n=10) 
 
 

















(d.46) F 15 
TR 
del375-377 Severe UIP Yes Family 2 
44 F 29 TR del375-377 None Yes Family 2 




not collected Lung Health Study 
48 
(d.49) F 32 
TERT 
IVS9-2 A→C Severe No Family 4 
44 
(d.54) F 25 
Dyskeratosis 
Congenita  Minimal UIP No Family 5 
49 
(d.62)       F 43 
TERT 
Arg599Gln None Yes COPDGene 
53 F 48 TERT Thr726Met None No COPDGene 
60 
(d.67) F 30 
Dyskeratosis 
Congenita None No Family 5 
62 
(d.63) F 37 
TR 
98G→A Moderate No Family 1 
63 
(d.66) M 20 
TERT 
Val747fsX20 Moderate UIP No Family 3 
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Figure 1. Functional consequences of telomerase variants identified by chronic obstructive 
pulmonary disease subjects.  A. Chromatograms of PCR-amplified variants identified by next-
generation sequencing.  B. Gel image of telomere repeat ladder generated from wild-type and 
mutant telomerases reconstituted in vivo and immunopurified.  The decreased intensity of the 
DNA repeat products generated by variant telomerases reflects impaired enzymatic activity of 
TERT Arg599Gln, Thr726Met and His925Gln.  TERT Asp868Asn is a negative control, 
catalytically defective in one of the aspartic acid residues essential for reverse transcription. 32P 
end-labeled 18mer oligonucleotide was included as an internal control for the recovery of DNA 
products.  C. Northern blot for TR levels from immuno-purified telomerases (top).  Western blot 
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for TERT expression in cells (bottom) was performed with anti-FLAG and anti-GAPDH 
antibodies for ectopically expressed FLAG-tagged TERT and endogenous GAPDH, respectively.  
D. Mean telomerase activity was derived from four activity assays from cell lysates prepared 
from two separate transfections.  E. Relative telomere length as measured by quantitative PCR in 
age-matched controls: (ages 37-64, n=8), TERT mutation carriers (ages 46-57, n=3) from 
COPDGene and the Lung Health Study (LHS), telomerase mutation carriers with pulmonary 
fibrosis (ages 45-63, TERT n=2, TR n=3), and COPDGene controls: a homozygous SERPINA1 
Glu366Lys mutation carrier (formerly coded Glu342Lys, rs28929474, PI*ZZ genotype, age 46) 
and the control TERT Arg653Cys variant (age 68).  F. Lymphocyte telomere length by flow 
cytometry and fluorescence in situ hybridization of a TERT mutation carrier and telomerase 
mutation carriers with pulmonary fibrosis relative to a nomogram of 400 controls.  Error bars 




























Figure 2. Radiographic and pulmonary function studies of telomerase mutation carriers 
with chronic obstructive pulmonary disease.  A-D. High resolution inspiratory computed 
tomography (CT) images from COPDGene study subjects with telomerase mutations.  The panels 
are each labeled at the top with the subject’s mutation.  Images from TERT mutation carriers 
show apical centrilobular emphysema (A-B and C-D).  In the subject with TERT 599Gln, 
bronchiectasis and a reticular, subpleural interstitial lung abnormality could also be appreciated 
(B).  E. Rate of change in FEV1 from baseline across the five years of the Lung Health Study in 
the subject with TERT His925Gln mutation.  The rate of change is graphed relative to the highest 
and lowest quartiles of the 5,887 study population (+/- standard error of the mean).   
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Figure 3. Pedigrees of telomere syndrome cases with emphysema.  A. Pedigrees of 
emphysema cases with telomere defects and their relatives’ clinical history.  DC refers to 
dyskeratosis congenita, a telomere syndrome defined by mucocutaneous features.  The * denotes 
individuals with DNA sequence data available and/or telomere length measurement performed.  
The bolded identifiers refer to individuals who carried the mutant gene and/or had very short 
telomeres (shown in B).  CS refers to a positive smoking history; NS refers to never smokers, and 
BMF refers to bone marrow failure.  The age at death from lung disease is indicated as “d.” B. 
Lymphocyte telomere length by flow cytometry and fluorescence in situ hybridization shows the 
short telomere defect in affected members relative to age-matched controls.  The nomogram was 
based on data from 400 controls.  C&D and E&F.  Apical and mid-lung chest CT cuts from two 
female cases (2.II.1 and 5.II.3, respectively) show severe apical emphysema with blebs.  In 
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 LHS, Lung Health Study; MAF, minor allele frequency  
 
*TERT sequence data from multi-ethnic cohort examined in Yamaguchi et al. NEJM 2005. 
**DNA from these controls of European descent was obtained through the National Disease Research Interchan 
†This variant was present in the COPDGene control group had comparable activity to wild-type telomerase 
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Supplementary Table 2. Clinical 
features of subjects with TERT 
mutations in the COPDGene and Lung 
Health Studies. 
 
Abbreviations: BMI, body mass index; 
FEV1, forced expiratory volume in 1 
second; FVC, forced vital capacity 
  
*Smoking history was recorded at study 
enrollment; pulmonary functions are from 
year 5 of study. 
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p.Pro1108Pro rs35033501 0.019 0.029 0.108 
g.1254594C>T 
p.Ala1062Thr rs35719940 0.014 0.022 0.036 
g.1255454G>A 
p.Val1035Val rs181612536 0.005 0.005 0 
g.1255520G>A 
p.His1013His rs33954691 0.104 0.100 0.181 
g.1260708G>T 
p.Arg951Arg - 0 0.003 0 
g.1264587G>A 
p.His925His rs34528119 0 0 0.012 
g.1264611C>T 
p.Thr917Thr - 0 0.003 0 
g.1268700C>T 
p.Thr839Thr rs140124989 0 0.003 0 
g.1271254G>A 
p.His816His - 0 0.003 0 
g.1278804C>T 
p.Val746Val - 0 0 0.012 
g.1278888,G,A 
p.Asp718Asp - 0 0.003 0 
g.1279430C>T 
p.Pro702Pro rs151055240 0 0 0.012 
g.1279439G>A  
p.Ala699Ala rs33963617 0.012 0.005 0 
g.1279505G>A 
p.Gly677Gly rs33956095 0.012 0.012 0.036 
g.1280387G>C 
p.Ala612Ala rs34170122 0 0 0.012 
g.1280411T>C 
p.Ala604Ala rs33959226 0.007 0 0.012 
g.1293767G>A 
p.His412Tyr rs34094720 0.002 0.002 0.012 
g.1294086C>T 
p.Ala305Ala rs2736098 0.279 0.275 0.446 
g.1294166C>T 
p.Ala279Thr rs61748181 0.032 0.041 0.060 
g.1295018C>T 
p.Arg29Arg - 0 0 0.012 
g.1295060G>A 
p.Arg15Arg - 0 0 0.012 
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Supplementary Figure 1. Filtering strategy for identifying telomerase variants for 
functional analysis.  Flow chart delineates a priori designed filtering strategy to identify rare 
telomerase variants in COPDGene and Lung Health Study (LHS). *Refers to publicly available 
VAAST software described in Yandell et al. Genome Research 2011.  EVS refers to the Exome 
Variant Server, MAF to minor allele frequency, and VCF to virtual contact file. 
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Supplementary Figure 2. Functional consequences of telomerase variant identified in 
COPDGene controls.  A. Gel image of telomeric DNA repeats generated from wild-type and 
variant telomerases reconstituted in vivo and immuno-purified.  The total intensity of the DNA 
repeat products generated by TERT Arg653Cys shows similar activity as wild-type telomerase.  
A 32P end-labeled 18mer oligonucleotide is included as an internal control for the recovery of 
DNA products.  B. Northern blot for TR levels from immuno-purified telomerases and western 
blot for TERT expression in cells.  Western blot performed with anti-FLAG and anti-GAPDH 
antibodies for ectopically expressed FLAG-tagged TERT and endogeneous GAPDH, 
respectively.  C. Mean telomerase activity from four independent activity assays from two 
separate transfections.  Enzymes were purified from cell lysates from two separate transfections 
and these experiments were done independent of those shown in Figure 1.  Error bars represent 
standard error of the mean.  P-values were calculated using Student’s t-test and are two-sided. 
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Supplementary Figure 3.  Conservation of mutated residues in TERT. A. Mutations fall in 
conserved catalytic domains of the telomerase reverse transcriptase.  B. Evolutionary 
conservation of TERT variants across seven species.  Mutated residues are labeled above the 
alignment.  Alignments were generated with the online tools Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) and BoxShade 
(http://www.ch.embnet.org/software/BOX_form.html).    
Supplementary Figure 4. Depth of coverage in next-generation sequence data.  Percent of 
sequences with 8X or greater coverage in the COPDGene (whole exome sequencing) and Lung 
Health Study cases (customized targeted panel).  For the COPDGene coverage analysis, 11 
exomes were randomly selected for this analysis using Binary Alignment/Map (BAM) files 
downloaded from the dbGaP portal.  For the Lung Health Study, the coverage reflects the mean 
from 76 samples that passed quality control.  The mean coverage calculation included exons and 
their flanking sequence.  SERPINA1 coverage reflects 20 nucleotides in exon 6 that contains the 
most common severe alpha-1 antitrypsin deficiency allele (PI*Z, rs28929474).   
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Short telomeres are a common defect in idiopathic pulmonary fibrosis, yet mutations in 
the telomerase genes account for only a subset of these cases.  We identified a family 
with pulmonary fibrosis, idiopathic infertility and short telomeres.  Exome sequencing of 
blood-derived DNA revealed two mutations in the telomere binding protein TINF2.  The 
first was a 15 base pair deletion encompassing the exon 6 splice acceptor site, and the 
second was a missense mutation, Thr284Arg.  Haplotype analysis indicated both variants 
fell on the same allele.  However, lung-derived DNA showed predominantly the 
Thr284Arg allele indicating the deletion seen in the blood was acquired and may have a 
protective advantage since it diminished expression of the missense mutation.  This 
mosaicism may represent functional reversion in telomere syndromes similar to what has 
been described for Fanconi anemia.  No mutations were identified in over forty 
uncharacterized pulmonary fibrosis probands suggesting mutant TINF2 accounts for a 
small subset of familial cases.  However, similar to affected individuals in this family, we 
identified a history of male and female infertility preceding the onset of pulmonary 
fibrosis in 11% of telomerase mutation carriers with TERT and TR mutations (5 of 45).  
Our findings identify TINF2 as a mutant telomere gene in familial pulmonary fibrosis, 
and suggest infertility may precede the presentation of pulmonary fibrosis in a small 
subset of adults with telomere syndromes. 
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The incidence of idiopathic pulmonary fibrosis (IPF) increases with age(1).  IPF also has 
a strong genetic component as evidenced by the fact that as many as one-fifth of affected 
individuals report another family member with idiopathic interstitial fibrosis(2).  Familial 
pulmonary fibrosis (FPF) is most frequently inherited as an autosomal dominant trait with 
age-dependent penetrance, and mutations in the telomerase genes are its most commonly 
identifiable cause(1).  Loss-of-function mutations in the core telomerase genes, TERT and 
TR, can be identified in 8-18% of probands with FPF(1).  More rarely, FPF displays X-
linked inheritance(3), and mutations in dyskerin, the X-linked telomerase holoenzyme 
component encoded by DKC1, have been linked to sporadic(4) and FPF(5), and account 
for ~1% of cases (unpublished).  Despite these recent discoveries, extra-pulmonary 
features of a telomere syndrome, such as liver disease and bone marrow failure, are often 
detected in pulmonary fibrosis patients who have short telomeres but in the absence of 
telomerase mutations suggesting the full complement of telomere genes in IPF is yet-to-
be characterized(6, 7).   
 
Lung disease is the most common manifestation of germline defects in telomere 
maintenance in adults(1, 8).  In more severe forms, telomere-mediated disease manifests 
in children in the disorder dyskeratosis congenita, a mucocutaneous condition classically 
defined by abnormal findings in the skin, nails and the oral mucosa, and marked by a 
predisposition to bone marrow failure(9).  In children with dyskeratosis congenita, 
mutations in DKC1, and in the telomere repeat interacting nuclear factor 2, TINF2, are 
the most common identified genetic causes(9).  Here, we report identifying by exome 
sequencing a mutation in TINF2 in an adult proband with FPF.   
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Materials and Methods 
Human Subjects.  Subjects were recruited to a Johns Hopkins study aimed at 
understanding the genetics and natural history of telomere-mediated disease(10, 11).  The 
study was approved by the Johns Hopkins Medicine Institutional Review Board, and all 
the participants gave written informed consent.   
 
Exome Sequencing.  Exome sequencing was performed using the SureSelect XT All 
Exome V4 kit and sequenced on the Illumina HiSeq 2000 platform as described(4).  
Variants were called using the Genome Analysis Tool Kit (GATK) and annotated using 
ANNOVAR (http://www.openbioinformatics.org/annovar/)(4).  Unique variants in 
telomere genes that were not found in the 1000 Genome Project Database and the Exome 
Variant Server were prioritized for additional studies.   
 
Telomere length and DNA sequencing.  Telomere length was measured on peripheral 
blood mononuclear cells by flow cytometry and fluorescence in situ hybridization(12).  
TERT and TR sequencing was performed as previously outlined(13).  TINF2 exon 6 was 
sequenced using the following primer sets: TINF2.E6F 5’-
CCTGGAGACAATATGGTGTGG-3’ and TINF2.E6R 5’-
AGGCTGTTGATCCAATCCTG-3’ (834 bp product).  Because DNA derived from 
formalin-fixed paraffin-embedded tissues is fragmented, we used two primer sets to 
genotype the two variants:  TINF2.E61F 5’-AGACCTTTTGAGGCAGTCCA-3’ and 
TINF2.E61R 5’-CCTTGAAGATGGTCCCTGAGGAAG-3’ for ∆15 (247 bp product), 
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and TINF2.E6.2F 5’-CAGGGACCATCTTCAAGGAC-3’ and TINF2.E6.2R 5’-
TGGAGGCTGCTCTTGTGCCCATG-3’ for the Thr284Arg missense (250 bp product).    
The proband had no deviations from the reference sequence at primer binding sites. 
 
Haplotype and clonality studies. Genomic DNA was extracted from peripheral blood 
using a Puregene kit (Qiagen, Valencia, CA), and from paraffin-embedded lung tissue 
using standard protocols.  Variants were confirmed by Sanger sequencing and the 
haplotype of adjacent variants was determined by TA cloning PCR products into a pCR4-
TOPO vector according to the manufactures’ protocol (Life Technologies) and 
sequencing individual clones.   
 
TIN2 expression studies.  We measured TINF2 mRNA levels in lymphoblastoid lines 
generated from the proband as well as healthy controls as previously described(3) using 
the following quantitative real time PCR primers: TINF2.E3F: 
GATTTTGGAGGCACAGGAAA and TINF2.E5R: CTGCATCCAACTCAGCACAT. 
To test the in vivo stability of mutant TIN2 proteins, we cloned the TINF2 genomic locus 
(inclusive of introns and exons) into a pCDNA5/FRT/TO vector (Life Technologies).  An 
N-terminal Myc tag was introduced immediately after the start codon to facilitate 
detecting the exogenous TIN2 protein.  Site-directed mutagenesis was used to introduce 
mutations and constructs were sequence verified.  Constructs were then transfected into 
HeLa Flp-In™ T-REx™ system, alongside the pOG44 vector, to generate isogenic, 
tetracycline inducible lines according to the manufacturer’s recommendations (Life 
Technologies).  Cells were treated with 1 µg/mL doxycycline for one week prior to 
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protein extraction.  Total protein was extracted after cells were lysed in RIPA buffer with 
protease inhibitors (Roche) and SDS-PAGE was performed using standard procedures 
followed by transfer to PVDF membranes.  Anti-Myc (clone 4A6, Millipore) and Tubulin 
(ab6046, Abcam) antibodies were used for immunoblotting and all membranes were 
scanned using an Odyssey Infrared Scanner (LI-COR).   
 
Results 
Exome sequencing identifies TINF2 mutations in a proband with FPF 
The proband presented with IPF at 49 years and died at age 50 (Figure 1A-1B).  She did 
not have premature graying, blood count abnormalities, or any mucocutaneous features of 
dyskeratosis congenita.  Her brother died from IPF at age 44.  Both the proband and her 
brother had a documented history of infertility that did not respond to reproductive 
assistance.  The family history was notable for two maternal uncles who died from 
cryptogenic liver disease in their 30s (Figure 1A).  Lymphocyte telomere length in the 
proband was at the first age-adjusted percentile, and granulocyte length was below the 
10th percentile (Figure 1C-1D).   There were no mutations detected in TERT or TR by 
Sanger sequencing; however, exome sequence analysis identified two mutations in 
TINF2.  The first was deletion IVS5-7–c.605-612 that spanned 15 base pairs across the 
intron 5-exon 6 boundary (hereon referred to as Δ15).  This mutation deleted the splice 
acceptor site, and thus predicted a functionally null TIN2 protein (Figure 2A-2B).  In 
addition, there was a heterozygous substitution in exon 6, c.851 C to G, which predicted a 
missense variant p.Thr284Arg (Figure 2A-2B).  The latter mutation had been described in 
an adult with short stature, dental loss, bone marrow failure, and lung disease(14), and 
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fell within the TINF2 exon 6 hotspot within which the vast majority of mutations reported 
in children with dyskeratosis congenita have been identified(15-17) (Figure 2A).   
 
Haplotype studies suggest acquired mosaicism of the TINF2 genotype in the blood 
To determine the phase of the mutations, we amplified and cloned the TINF2 region 
encompassing the variants, and quantified the proportion of each clone by Sanger 
sequencing.  Among the clones sequenced from blood-derived DNA (n=56), the wild-
type allele was in 34%.  The ∆15 and Thr284Arg mutations were detected in cis in 45% 
of the clones.  The remaining clones contained either the ∆15 (17%) or Thr284Arg (4%) 
alone.  The clonal heterogeneity suggested two compatible possibilities.  The first is that 
there was mosaicism in the blood.  The second is that there was low grade polymerase-
mediated template switching in the PCR amplification reaction that contributed to the 
allele heterogeneity we detected.  We tested for template switching by mixing plasmids 
that carried the Δ15 and Thr284Arg separately, and found rare PCR products that 
contained only wild-type TINF2 or both products in cis.  Template switching may thus 
explain the rare single variant clones detected in the blood.  To test for mosaicism, we 
sequenced genomic DNA extracted from lung biopsy tissue and found the Thr284Arg 
variant predominated (40% of clones, 8 of 20 screened).  Only rarely, in 8% of clones (2 
of 26), the deletion was detected.  These data were consistent with blood-derived 
contamination since the vast majority of blood-derived DNA clones contained the 
deletion (61%, Figure 2C).  The results indicated the Thr284Arg was the germline 
mutation and the Δ15 represented a secondary acquired variant in the blood.   
 
 65 
Segregation studies support mutant TINF2 segregates with IPF phenotype 
To test for segregation in the family, we sequenced genomic DNA from the proband’s 
father and sister who had no telomere syndrome features and normal telomere lengths 
and found both mutations were absent (Figure 1A, 1C-1D).  These findings, along with 
the maternal history of liver disease, implicated the patient’s mother as a likely obligate 
carrier of the Thr284Arg mutation (Figure 1A).   
 
TINF2 deletion disrupts protein expression 
We examined the functional consequences of the mutations on endogenous TIN2 
expression by measuring the mRNA levels in cells derived from the proband and found a 
reduction by quantitative real time PCR (37% compared with 100+21%, n=4 controls).  
This was consistent with the Δ15-Thr284Arg mutation causing nonsense-mediated decay.  
To directly examine whether the Δ15 mutation affected the expression of the missense 
mutation, we cloned the TINF2 genomic sequence under the regulation of a tetracycline 
inducible CMV promoter in HeLa cells (Figure 3A).  We compared the protein stability 
of TIN2 encoded by wild-type, Thr284Arg, and ∆15-Thr284Arg.  For additional 
comparison, we included TIN2 Arg282His, the TINF2 mutation which is the most 
commonly identified in severe pediatric telomere syndrome cases(15).  Both missense 
TINF2 mutations produced proteins that had comparable levels to wild-type by 
immunoblot (Figure 3B).  However, the ∆15-Thr284Arg mutation abolished the long 
isoform of TIN2, and produced lower levels of a degenerate product that was smaller 
than the TIN2 short isoform consistent with the splice junction mutation disrupting 
protein expression (Figure 3B).     
 66 
 
TINF2 mutations are a rare cause of FPF  
We had previously screened 73 FPF probands for TINF2 mutations in exon 6(6).  In this 
study, we screened 40 additional FPF probands and found no mutations.  These data 
suggested that TINF2 mutations are a rare cause of FPF and explain the genetic risk in 
approximately 1% of cases.   
 
A history of infertility may precede the onset of IPF in telomere syndrome cases 
In both the proband and her brother, infertility preceded the onset of IPF and we tested 
whether this pattern was recurrent in other telomere syndrome cases.  We reviewed the 
history of 45 consecutively evaluated pulmonary fibrosis patients with telomerase 
mutations in our Johns Hopkins-based study and documented a history of referral for 
reproductive assistance in five other cases (11%, 3 male and 2 females, TERT n=3, TR 
n=2).  In all these cases, the infertility evaluations preceded the onset of IPF.  Among the 
total of the seven cases, including the two in this family, reproductive assistance led to a 
successful birth in three cases (43%, 2 male, 1 female).   
 
Discussion 
Here we report mutations in TINF2 in association with FPF.  Our observations add to a 
growing body of literature underscoring the intimate connection between telomere 
dysfunction and IPF etiology and risk.  The proband and her affected brother with IPF 
had no features of classic dyskeratosis congenita and no bone marrow failure, the 
predominant phenotypes heretofore linked to TINF2 mutations that usually manifest 
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before the age of 10(15-17).  As such, our exome findings are notable and indicate the 
spectrum of disease associated with TINF2 mutations may at times, albeit rarely, include 
adult-onset disease in the absence of hematologic abnormalities.  With the addition of 
TINF2, there are six known FPF genes(4, 5, 13, 18-20).  Four of these fall in the telomere 
pathway, and together they explain approximately one-fifth of the familial clustering of 
pulmonary fibrosis (Figure 3C).   
 
Telomere length is the primary determinant of disease severity in telomere syndromes(9, 
11).  Severe telomere shortening usually manifests in children with aplastic anemia, while 
attenuated telomere defects are associated with adult-onset disease complicated by 
pulmonary fibrosis or emphysema(8, 9, 11).  Pulmonary fibrosis has been reported in two 
isolated cases adult cases with classic dyskeratosis congenita and aplastic anemia in 
association with TINF2 mutations(14, 21).  These two examples further underscore the 
rare nature of the isolated FPF presentation in the family we report here.  The 
determinants of disease severity beyond telomere length in TINF2 mutation carriers are 
not known, but it may be that some mutations are hypomorphic such as in this case given 
the adult-onset clinical presentation, or that other genetic modifiers that are yet-to-be 
identified affect the severity of the telomere defect.  It is also possible that the acquired 
deletion in the blood may have had a protective effect against a bone marrow failure 
phenotype in the proband. 
 
The mosaicism we report here points to functional reversion as a likely acquired event 
and, to our knowledge, this has not been reported in the telomere syndromes.  Somatic 
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reversion is known to occur in genome instability syndromes and has been described in 
dyskeratosis congenita patients with TR mutations(22).  In these cases, homologous 
recombination mediates reversion to the wild-type allele in the blood(22).  In our study; 
however, we found evidence suggesting an acquired clonal event in the blood.  The 
mechanisms by which this occurred are unclear, but because the acquired deletion 
abolished the expression of the missense mutation, it may have given a growth advantage 
to the hematopoietic clone where it arose (Figure 3D).  The selective growth advantage 
may have arisen because TINF2 heterozygous null mutations are better tolerated than 
exon 6 point mutations in vivo.  Functional correction has been previously documented in 
Fanconi anemia where acquired insertions and deletions in hematopoietic clones restore 
mutant protein function(23).  Our report indicates this form of mosaicism may also occur 
in telomere disorders and this possibility should be considered in the genetic evaluation 
and counseling of individuals at risk.    
 
Although the mechanisms by which TINF2 mutations cause telomere shortening remain 
to be fully elucidated, several pieces of evidence point to a dominant negative genetic 
model.  First, the human mutations cluster in a discrete hotspot.  Moreover, TINF2 
mutations have been suggested to interfere with telomere elongation by telomerase in cell 
culture systems(24).  The example we report here of an acquired deletion in the blood 
abolishing expression of the mutant TIN2 further supports this evidence.  Congruent with 
this model, Tin2 heterozygous mice that carry an analogous TIN2 hotspot mutation 
acquire telomere shortening when bred successively for multiple generations(25).  
Altogether, these observations suggest that TINF2 exon 6 missense mutations likely 
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interfere with normal telomere function and that their effect on telomere length is likely 
more deleterious than heterozygous null alleles.  Additional human cell line experiments 
are needed to fully test this model.  Although the reversion may have protected against 
the bone marrow failure phenotype in the proband, to date reversion has not been 
detected before the age of 40(22).  It is therefore possible that in the missense mutation in 
this family represents a hypomorphic allele.  The short telomere length in the proband is 
consistent with the possibility that the reversion may have occurred later in life, although 
telomere elongation may take up to two generations to be restored in wild-type offspring 
of telomerase mutation carriers(26, 27).   
 
The presentation in this family highlights an association between short telomeres and 
decreased fertility in humans.  Telomere shortening causes infertility and germ cell 
apoptosis in male mice(28, 29), and has more recently been linked to decreased fertility 
in female mice(30).  Our retrospective observations in telomerase mutation carriers with 
pulmonary fibrosis suggest infertility, both male and female, may be a first telomere 
syndrome presentation in some cases.  As in the index family here, the infertility 
phenotype may be more pronounced in later generations because of genetic anticipation, 
the known pattern of earlier, more severe disease seen in autosomal dominant families 
with telomere syndromes(31, 32).   This association between telomere shortening and 
infertility has implications for the care of telomere syndrome patients as affected patients 
may need earlier referral for reproductive assistance.  A family history of infertility in 
association with pulmonary fibrosis may also raise the suspicion for an inherited telomere 
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syndrome.  The telomere syndrome diagnosis should in turn be considered in the workup 
of unexplained infertility especially in the context of other telomere syndrome features.   
 
The genetic diagnosis of telomere-mediated pulmonary fibrosis has important 
implications for treatment.  In the lung transplant setting, pulmonary fibrosis patients are 
prone to otherwise rare complications caused by immunosuppressive medications that 
include excessive transfusion support for cytopenias, renal failure, and gastrointestinal 
bleeding(33).  The link between TINF2 and FPF therefore has implications for genetic 







Figure 1.  Clinical features of family with pulmonary fibrosis.  A. Pedigree of index case with 
summary of the clinical history designated below.  The proband is delineated by the arrow.  Male 
family members are squares and females in circles.  The black shade refers to individuals with 
clear telomere phenotypes and gray to probable obligate carrier of a TINF2 mutation.  TINF2 
genotypes are denoted adjacent to the individuals sequenced. WT refers to the wild-type reference 
sequence, and ∆15 refers to the deletion at the intron 5-exon 6 junction.  The C/G genotype refers 
to the missense mutation.  B. Lung window images from a chest CT scan from the proband 
showing peripheral honeycombing predominantly in the lung bases typical of IPF.  The usual 
interstitial pneumonia (UIP) histology was subsequently confirmed on lung biopsy.  C. 
Lymphocyte telomere length of affected and unaffected individuals from (A) are plotted relative 
to age-matched controls.  D. Granulocyte telomere length relative to age-matched controls.  
Nomograms and percentiles were based on data from 192 controls.  The pedigree identifiers refer 
to individuals in (A).   
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Figure 2. TINF2 mutations studies in a proband with pulmonary fibrosis.  A. Schema of 
TINF2 genomic locus showing position of mutations detected by exome sequencing above.  The 
exon 6 hotspot is highlighted in red.  B. Chromatogram traces of sequence data from the proband 
derived from blood and lung genomic DNA.  C.  Percentage of each of the PCR-amplified 








Figure 3.  Consequences of mutations on TIN2 protein stability and proposed model of 
functional consequences of TINF2 mutations.  A. Schema of TINF2 at its genomic locus 
inserted in FRT sites in HeLa cells.  B. Immunoblot of Myc-tagged TIN2 expressed from a single 
promoter shows its two isoforms, TIN2L (long form) and TIN2S (short form) as described in 
Kaminker and Campisi Cell Cycle 2009.  A third band, possibly representing a third TIN2 
isoform, is also seen at an intermediate size between TIN2L and TIN2S.  In contrast to the wild-
type, and the two missense variants, ∆15-Thr284Arg abolishes the expression of TIN2L and 
creates low levels of a smaller degenerate protein product below the expected size for TIN2S.  C. 
Pie chart illustrates the six known familial pulmonary fibrosis genes and their frequency 
estimates.  D. Schema of model summarizing the putative functional consequences of the TINF2 
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We report radionecrosis as a first manifestation of a germline mutation in telomerase.  A 
60 year old woman presented with defective wound healing after multiple surgical 
explorations of the chest wall to exclude breast cancer recurrence.  At age 42 on routine 
mammography, she was diagnosed with stage I estrogen receptor positive left breast 
infiltrating ductal carcinoma. Lumpectomy with axillary node dissection revealed T1N0 
disease.  Adjuvant radiation therapy consisted of 50.4 Gy in 28 fractions followed by a 10 
Gy boost in five fractions to the tumor bed.  She did well for twelve years when a left rib 
fracture was incidentally noted on imaging; this prompted multiple needle biopsies which 
showed atypia but no malignancy.  Open surgical biopsy revealed the anterior ribs within 
the radiation field were replaced with soft tissue, but no malignancy was found.  The 
post-operative course was complicated by multiple wound infections requiring surgical 
debridement and failed healing of skin grafts that left her with an open chest wall wound 
(Figure 1A).  She was evaluated at our center for a second opinion.   
 
CT imaging showed fractured left ribs and chest wall abnormalities consistent with 
radionecrosis.  In addition, in the contralateral lung, there was basilar honeycombing 
characteristic of idiopathic pulmonary fibrosis (IPF) (Figure 1A-1B).  The family history 
revealed two siblings who died from IPF and myelodysplastic syndrome, a complex 
pathognomonic for the short telomere syndrome diagnosis(1).  Genetic evaluation 
revealed a deleterious mutation in the telomerase RNA gene, TR, that was also found in 
her siblings (n.80, T>A).  The mutation predicted disrupting TR’s essential pseudoknot 
domain, and was associated with short telomere length, below the age-adjusted 10th 
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percentile (Figure 1C).  Additional chest wall reconstruction was deferred given the 
known risk of respiratory failure after elective surgery and anesthesia in IPF patients(2).  
In the subsequent year, her wound improved with conservative care, but she developed 
worsening respiratory symptoms, and subsequently died cancer-free from end-stage lung 
disease.   
 
In order to test whether short telomeres may predispose to radiosensitivity, we utilized a 
modified cell survival assay that is diagnostic of double strand break syndromes such as 
ataxia-telengiectasia (A-T)(3, 4).  We examined lymphoblastoid cells derived from seven 
other telomerase and telomere gene mutation carriers (Figure 1C).  Four of them were 
asymptomatic, two had IPF, and one had bone marrow failure.  Cells from these subjects 
showed significantly compromised survival compared to controls and were similarly 
sensitive to A-T patients (Figure 1D-E).  In 3 of 7 cases (43%), the surviving fraction at 1 
Gy fell below at or below 21%, a threshold considered diagnostic of A-T in some 
settings(3).  Neither the age nor the severity of the telomere defect predicted the 1 Gy 
surviving fraction in these subjects. 
 
Radiosensitivity and radionecrosis are rare complications of treatment, but they are well-
documented complications in patients with defective DNA double strand break repair 
such as A-T(5).  The data we show here indicate patients with short telomere syndromes 
are similarly radiosensitive.  To our knowledge, this is the first clinical case of 
radionecrosis in a telomerase mutation carrier.  Sensitivity to radiation in the setting of 
telomere length abnormalities was first documented in telomerase null mice with short 
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telomeres(6), and our data establish the relevance of these observations to the clinical 
setting. 
 
Syndromes marked by short telomeres manifest as IPF, emphysema and aplastic 
anemia(7).  Mutations in telomere and telomerase genes are the most common cause of 
familial pulmonary fibrosis cases accounting for one-third of cases(7); they also rival 
alpha-1 antitrypsin deficiency as a risk factor for emphysema(8).  Short telomere 
syndrome patients most often present in mid-late adulthood and have no associated 
dysmorphic features.  A cancer diagnosis is estimated to affect up to 10% of severe cases, 
such as in dyskeratosis congenita, and predominantly manifests as myelodysplasia-acute 
myeloid leukemia and, more rarely, squamous cell head and neck carcinomas(9). There is 
a paucity of data regarding cancer treatment outcomes in this population.  After 
hematopoietic stem cell transplantation, pulmonary fibrosis is a prevalent life-threatening 
complication, and lung shielding has evolved as a standard to minimize this risk(10).  
Awareness of this genetic diagnosis is important in clinical settings where ionizing 
radiation is utilized, such as in assessing the risk of X-ray-based imaging as a screening 
tool in pulmonary fibrosis, as well as in a preference for radiation-sparing regimens in 
hematopoietic stem cell transplantation.  Suspected patients who have a suspicious 
personal or family history, especially of IPF-emphysema or myelodysplastic syndrome, 








Figure 1. Clinical features and cell survival of cells with short telomeres after irradiation. A. 
Non-healing open left anterior chest wall wound (arrow) after open biopsy and failed grafts. B. 
Basilar honeycombing typical of idiopathic pulmonary fibrosis (arrows). C. Telogram shows 
telomere length of mutation carriers relative to age-matched controls (n=192). Telomeres were 
measured in peripheral blood lymphocytes by flow cytometry and fluorescence in situ 
hybridization.  The labels indicate the mutant telomere gene in each of the cases. The red circles 
refer to individuals whose lymphoblastoid cell lines were studied in vitro (D and E).  D. Dose 
response curve shows the surviving fraction of cells at each dose of ionizing radiation.  Means 
reflect data from each group of controls, short telomere and ataxia telengiectasia (A-T) cells.  
Each cell line was assayed in quadruplicate, and the experiment was replicated twice.  E. 
Individual data points for each of the cases at 1 Gy, a threshold which has been shown to useful in 
the diagnosis of DNA double strand break syndromes (Sun et al. 2002).  Error bars refer to the 
standard error of the mean.  *, ** and *** refer to two-sided P-values < 0.05, <0.01 and <0.001, 
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Abstract 
Chronic obstructive pulmonary disease and pulmonary fibrosis have been hypothesized to 
represent premature aging processes.  The two phenotypes at times cluster in families, but 
the genetic basis is not understood.  Short telomeres have been shown to influence the 
development and progression of these phenotypes, yet among even telomere-mediated 
familial lung disease there is substantial locus heterogeneity.  Compromised telomerase 
RNA (TR) levels are one molecular mechanism of disease and can be measured in patient 
cells.  Using TR levels as a screening tool, we identified rare, frameshift variants in the 
gene nuclear assembly factor 1, NAF1, a box H/ACA RNA biogenesis factor, in 
pulmonary fibrosis-emphysema patients. Mutations segregated with short telomere length, 
low TR levels, and extrapulmonary manifestations including myelodysplastic syndrome 
and liver disease.  A truncated NAF1 was detected in cells derived from patients, and in 
cells where the frameshift was introduced by genome editing, telomerase RNA levels 
were compromised.  The mutant NAF1 lacked a conserved C-terminal motif, which we 
show is required for nuclear localization. Our studies identify a new disease gene in 
pulmonary fibrosis and emphysema, and outline the first report of haploinsufficiency for 
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Introduction 
Lung disease is the third leading cause of death in the United States(1).  Chronic 
obstructive pulmonary disease (COPD), which includes emphysema, along with 
pulmonary fibrosis (PF), are major culprits.   Both diseases have been shown to co-cluster 
at times in families that show autosomal dominant inheritance; however, the genetic basis 
in the majority of these cases is not understood(2-5).  A number of observations have 
linked the etiology of PF and emphysema to premature aging and to abnormalities in 
telomere length maintenance(3, 6-10).  For example, abnormally short telomere length is 
a frequent finding in at least half of idiopathic PF patients(6, 11).  Moreover, clinical 
features of a short telomere syndrome, including bone marrow failure/myelodysplastic 
syndrome, liver disease and infertility, are common in patients with sporadic and familial 
PF as well as in some patients with emphysema(6, 12-15).  The diagnosis of a short 
telomere syndrome in these patients is relevant for patient care because the defect is 
systemic, and they show exquisite sensitivity to otherwise tolerated medications and 
procedures, especially in the lung transplantation setting(16).  Mutations in the core 
telomerase enzyme components, TERT, the reverse transcriptase, and TR, the telomerase 
RNA component, were the first to be linked to inherited forms of PF; they are the most 
common identifiable genetic abnormality, and collectively they explain 15-20% of 
familial PF cases(2, 17-19).  Smokers with telomerase mutations, especially women, are 
also prone to developing emphysema, alone or combined with PF(3).  In smokers with 
severe, early-onset emphysema, TERT mutations were recently reported to be a risk 
factor in a proportion comparable to α-1 antitrypsin deficiency(3).  However, in 70% of 
families with autosomal dominant pulmonary fibrosis, the genetic basis remains 
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uncharacterized(2), and, aside from TERT, the other heretofore identified telomere genes, 
TR, DKC1, TINF2, RTEL1 and PARN, each explain only 1-3% of familial cases(13, 15, 
20, 21).   
 
Vertebrate TR shares with a family of non-coding RNAs a 3’ box H/ACA motif; this 
domain is required for its stability and assembly into a mature telomerase holoenzyme 
complex(22-24).  To overcome the locus heterogeneity seen in familial PF-emphysema, 
we took here the approach of classifying genetically uncharacterized cases by molecular 
abnormalities using TR levels as a stratification tool and examining candidate genes that 
have been implicated in TR biogenesis. 
 
Results 
Rare variants in NAF1 segregate with short telomere phenotype and low TR levels  
To probe the genetic basis of uncharacterized familial PF-emphysema, we performed 
whole genome sequencing on five unrelated probands who had abnormally short 
telomeres, extra-pulmonary telomere syndrome features, and a family history consistent 
with autosomal dominant inheritance (fig. S1, A to C), but found no shared rare variants.  
To narrow the candidates, we sub-classified the cases by TR levels in lymphoblastoid cell 
lines (LCLs).  Three probands had half the TR levels of controls as measured by 
quantitative reverse transcription real-time PCR (qRT-PCR) (fig. S1D), and we selected 
these for a candidate search that prioritized TR biogenesis genes.  We included pontin 
(RUVBL1) and reptin (RUVBL2), ATPases that facilitate telomerase assembly(25), as 
well as GAR1, SHQ1 and NAF1, which are involved in TR biogenesis(26-31).  In JH1, a 
	   87 
proband with combined PF and emphysema, we found a heterozygous single base-pair 
insertion in exon 7 of NAF1, c.984insA, which predicted a premature stop after a short, 
out-of-frame amino acid sequence, S329Ifs*12 (Fig. 1A and B).  This variant had not 
been seen in 9,006 individuals reported in public databases, and was absent in 134 
controls we additionally sequenced (Fig. 1C).  S329Ifs*12 was present in the proband’s 
two siblings who had short telomere disease phenotypes, as well as in her mother who 
died from emphysema, but was absent in unaffected relatives (Fig. 1A and fig. S2).  An 
affected sibling similarly had low TR levels relative to controls (Fig. 5D), as well as 
abnormally short telomeres, while non-carriers in the family had longer telomeres (Fig. 
5E and F), albeit the telomeres were not as long in the proband’s son, consistent with the 
known inheritance of short telomeres in offspring of telomerase mutation carriers(32-34). 
 
To examine the prevalence of mutations, we sequenced NAF1 in 25 additional genetically 
uncharacterized cases with PF, alone or combined with emphysema.  Among them, we 
identified JH2, a woman with sporadic idiopathic PF and bone marrow failure, who 
carried a heterozygous two base-pair deletion, also in exon 7, c.956_957delAA, which 
predicted a frameshift followed by a premature stop, K319Rfs*21 (Fig. 1A and B).  This 
second variant was also absent from the public databases and from the controls we 
sequenced (Fig. 1C).  Leukocyte telomere length was abnormally short in this patient 
(Fig. 1E and F), and her peripheral blood cells failed several transformations with 
Epstein-Barr virus, presumably because of the severity of the telomere defect. Altogether, 
rare NAF1 variants were detected in two of 30 (7%) of genetically uncharacterized PF-
emphysema patients in our cohort. 
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A truncated NAF1 protein in mutation carriers 
We examined the consequences of the frameshifts that we identified on protein stability.  
NAF1 is a 494 amino acid protein, and, if the truncated proteins were stable, a 339 and 
338 amino acid product would be seen in JH1 and JH2, respectively (Fig. 2A).  Protein 
lysates from patient-derived LCLs from JH1 and her sibling showed there was nearly half 
the level of full length NAF1 compared to unrelated controls and to the relative who did 
not carry the mutation. A lower molecular weight species that was only seen in mutation 
carriers was also detected; it corresponded to the predicted weight of the truncated 
protein (Fig. 2B).  To determine whether the frameshift mutations could give rise to a 
shortened species, we expressed N-terminal Myc-tagged K319Rfs*21 and S329Ifs*12 
(hereon K319fs and S329fs, respectively) under the control of a doxycycline-inducible 
CMV promoter at an isogenic locus in HeLa cells.  In this system, we detected shortened 
NAF1 proteins that migrated at a molecular weight similar to the truncated species we 
observed in patient-derived cells, and to the predicted product for K319fs, respectively 
(Fig. 2C).  When overexpressed, these mutants did not compromise TR levels (85% and 
100% of control levels for K319fs and S329fs, respectively, P=0.7 for both), indicating 
they did not exert a dominant negative effect.  In contrast, shRNA knockdown of the 
endogenous NAF1 decreased TR levels (Fig. 2D to F).  The decrease in overall TR was 
independent of dyskerin because its levels were intact in LCLs from mutation carriers 
(Fig. 2B).  These data suggested that NAF1 loss-of-function likely underlies the 
telomerase insufficiency in the patients we identified. 
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Disease-associated NAF1 alleles are functionally deleterious 
To directly test the pathogenicity of the rare alleles, we compared their capacity to rescue 
TR after NAF1 knockdown in HeLa cells (Fig. 2G).  K319fs failed to rescue TR, but 
S329fs was comparable to the wild-type allele in this system, suggesting it had residual 
function when overexpressed (Fig. 2H).  To test the consequences of the S329fs allele on 
TR stability at its endogenous levels, we used CRISPR/Cas9 to knockin the mutation in 
pseudo-diploid HCT116 cells.  A homozygous mutant clone, NAF1S329fs/S329fs, was 
derived, and it expressed only the truncated NAF1 species (Fig. 2I and J).   This clone 
exhibited significantly decreased TR levels (31% and 14% of control cells by qRT-PCR 
and northern blot, respectively, Fig 2K to I).  Restoring full length NAF1 by lentiviral 
cDNA transduction partially rescued TR, consistent with a NAF1-dependent effect on 
telomerase levels in these cells (fig. S3, A to C).   
 
NAF1 mutations impair nuclear localization  
To understand how the mutant NAF1 proteins compromised TR, we examined the 
conserved domains within the truncated regions.  K319fs and S329fs fell near a bipartite, 
lysine rich nuclear localization signal (NLS) that is functionally conserved in yeast(31, 35, 
36) (Fig. 3A and fig. S4).  K319fs disrupted the entire NLS, but S329fs interrupted only 
half the sequence (Fig. 3A).  Additionally, K319fs, interrupted a highly conserved portion 
of the Gar1 homology domain (Fig. 3A and fig. S4).  To test whether the truncated NAF1 
proteins were defective for nuclear localization, we tracked the nuclear fraction of Myc-
tagged proteins by immunufluorescence in the modified HeLa cells after treatment with 
leptomycin B, a blocker of nuclear export.  Leptomycin B abolished the export of 
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NAF1WT and it accumulated in the nucleus, as expected (fig. S5A).  In contrast, when 
four lysines, previously linked to nuclear localization(36), were mutated to alanine 
(NAF14K>4A), there was a greater fraction in the cytoplasm (Fig. 3A to D).  Similar to 
NAF14K>4A, NAF1K319fs and NAF1S329fs, were both enriched in the cytoplasm (Fig. 3C 
and D).  Interestingly, the nuclear localization defect was more pronounced for 
NAF1K319fs, consistent with our earlier results showing NAF1S329fs is hypomorphic (Fig 
3C and D, Fig. 2H).  We also tested whether a nuclear localization defect was present in 
NAF1S329fs/S329fs HCT116 cells and documented a decreased NAF1 nuclear fraction by 
Western blot (mean 44% of controls, n=5 experiments, range 33-69%, P=0.002, 
representative gel in Fig. 3E).  To assess the functional relevance of these observations, 
we probed whether an exogenous NLS can rescue the localization.  We added an 
exogenous SV40-derived NLS sequence onto the N-terminus of each of the mutant 
proteins, and found that the nuclear localization was restored (Fig. 3A to D).   However, 
for NAF1K319, the exogenous NLS could not rescue TR levels after shRNA knockdown, 
suggesting the Gar1 homology domain altered in this mutant protein is also required for 
TR stability (fig. S5, B and C).   
 
Discussion 
We report here that NAF1 loss-of-function mutations cause a short telomere syndrome 
that manifests as PF-emphysema as well as extrapulmonary telomere-mediated disease.  
Although mutations in the core telomerase components, TERT and TR, cause 
haploinsufficiency and autosomal dominant disease(17, 33, 37, 38), mutations in other 
telomerase biogenesis factors previously identified have shown recessive inheritance(39-
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41).  NAF1 may thus be unique among the RNA biogenesis factors with regard to its full 
dosage requirement for telomerase and telomere maintenance.  Supporting this 
observation, a SNP near the NAF1 locus is the only variant near a telomerase-related 
gene to be identified in genome wide association studies for telomere length, aside from 
TERT and TR(42, 43).  rs7675998, which falls 40 kb downstream of NAF1, has an effect 
size on telomere length similar to SNPs near TERT and TR(42, 43).  Our data suggest that 
this SNP affects telomere length by compromising NAF1 levels.  Interestingly, 
rs7675998 has also been reported to be protective against melanoma(44).  This likely also 
occurs by promoting telomere shortening, which is well-established to protect against 
melanoma risk(2).  The exquisite sensitivity of telomere length maintenance to NAF1 
levels that we identified here in Mendelian short telomere syndromes therefore sheds 
light on the molecular basis of disorders with complex inheritance.   
 
The role of telomerase and telomere shortening in mediating lung disease has been 
studied in animal models.  Although telomerase insufficiency alone does not cause lung 
pathology, telomerase null mice with short telomeres develop emphysema when exposed 
to cigarette smoke(8).  The pathology has been linked to a lung intrinsic factors including 
cumulative injury caused by the genotoxic damage from cigarette smoke that is additive 
to existing telomere dysfunction in epithelial cells(8).  When telomere dysfunction is 
induced in alveolar stem cells, they show hallmarks of senescence, and there is a lung 
remodeling that manifests in an emphysema-like phenotype that is associated with as 
recruitment of an inflammatory response resembling that seen in COPD(9).  Our findings 
here, in the context of the published literature, highlight how telomere shortening is a 
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relevant mechanism for PF-emphysema susceptibility in a subset of patients beyond those 
with mutations in the telomerase core components.  It is thus possible that efforts to 
reverse the telomere defect, through regenerative approaches, will influence the natural 
history of these progressive pathologies in the subset of patients with telomere-mediated 
lung disease. 
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Materials and Methods 
Study Design.  The goal of this study was to discover novel genes that cause familial 
short telomere syndromes.  Probands with IPF-emphysema with pedigrees that show 
autosomal dominant inheritance were stratified by TR levels and genomic DNA was 
analyzed by whole genome sequencing and candidate gene examination.  To test whether 
variants identified were disease-causing, their segregation with the short telomere 
phenotype and TR levels were examined, and their frequency in healthy controls was 
queried.  To understand the functional consequences of mutations, a multi-species 
alignment was generated.  The cellular and molecular consequences of the mutations 
were studied in patient-derived LCLs as well as in an inducible HeLa system where 
mutants were knocked in at an isogenic locus. CRISPR/Cas9 editing was used to 
introduce the mutations at the endogenous locus and study the effect on TR stability. All 
the immunofluorescence and northern blotting studies were performed blinded to 
genotype.  All the studies were performed at a minimum of triplicate.  Other details 
regarding the replication of the data are included in the respective figure legends. 
Subjects. Subjects were recruited from 2007 to 2015 as part of the Johns Hopkins 
Telomere Syndrome Registry. Entry criteria included familial pulmonary fibrosis-
emphysema or familial/sporadic cases with classic short telomere syndrome phenotypes 
and molecularly documented short telomere length as described(12, 45, 46).  Control 
DNA (n=134) was obtained from the National Disease Research Interchange (NDRI) 
from individuals who had no lung disease, and the donors self-identified as being of 
European ancestry.  Peripheral blood mononuclear cells (PBMCs) were transformed with 
	   94 
Epstein-Barr virus as described(47).  Among the 25 genetically uncharacterized cases that 
were screened, sixteen had familial PF, and nine had sporadic PF-emphysema with 
extrapulmonary telomere syndrome features.  The study was approved by the Johns 
Hopkins Medicine Institutional Review Board and all the subjects gave written, informed 
consent. 
Telomere length measurement.  Telomere length for all the studies shown was measured 
by flow cytometry and fluorescence in situ hybridization (flow-FISH) in a Johns Hopkins 
CLIA-certified facility as described(48).  The flow-FISH method described includes 
extensive internal controls including MESF beads, cow thymocyte internal control, and 
standards included on each plate prepared using a robotic system as described(48).  The 
facility’s intra-assay coefficient of variation (CV) among the three replicate samples had 
a mean of 1.2% and 0.8% and the inter-assay CV was 1.8% and 0.7% for lymphocytes 
and granulocytes, respectively.  Telomere data were plotted relative to a validated 
nomogram derived from healthy controls as previously described(18).   
DNA extraction, next-generation sequencing and variant filtering. Genomic DNA from 
peripheral blood was isolated using the PureGene Blood Core Kit (Qiagen). For whole 
genome sequencing, genomic DNA libraries were prepared without amplification with 
the TruSeq DNA PCR-Free sample preparation kit (Illumina).  Short read, paired end 
sequencing was carried out with the Illumina HiSeq2000 platform.  Reads were aligned 
to the GRCh37 reference genome with the Illumina pipeline v2.0.2. Average depth of 
coverage was 45.1x and 98.3% of the genomes were covered at ≥20x.   
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VCF files were annotated using ANNOVAR, and the data were filtered based on their 
predicted effect on protein sequence (nonsense, frameshift, missense, and splice-altering), 
as well as their minor allele frequency (<0.0001) in each of the following publicly 
available sequencing databases: dbSNP build 129 (http://www.ncbi.nlm.nih.gov/SNP/), 
ESP6500 (http://evs.gs.washington.edu/EVS), and 1000Genomes 
(http://browser.1000Genomes.org).  These databases were last accessed August 1, 2015. 
NAF1 sequencing.  Genomic DNA was derived from peripheral blood except for a 
sample which was from archived formalin-fixed paraffin embedded (FFPE) tissue and 
another from dried blood spots.  To screen for NAF1 mutations, we used a TruSeq 
Custom Amplicon Panel (Illumina) that included the coding NAF1 sequence as well as 
flanking intronic sequence as described(3).  In two cases, we analyzed the NAF1 
sequence from existing exome data that were generated and analyzed using previously 
described methods(15).  Sanger sequencing was used to confirm variants and test for 
segregation in family members.  The following primers were used for amplification and 
sequencing of NAF1 exon 7: 5’-GGCTGATTACTGGCCTGTGTTAA-3’ (forward) and 
5’-CCTCCTGCTATGTAATGGCTCTAAA-3’ (reverse) (476 bp).  For FFPE tissues, 
primer sequences were modified to generate a smaller amplicon: 5’-
GCATAATAGGCTTATTTTCTTCACC-3’ (forward) and 5’- 
CAGAGAGAACCCAGATGTTTCCTTC-3’ (reverse) (294 bp).   
Telomerase RNA (TR) quantitative reverse transcription real-time PCR (qRT-PCR). 
Total RNA was extracted with the RNeasy Mini Kit (Qiagen) as recommended except 
DNAse digestion was performed using twice the volume and for an extended of 1 hour.  
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Random hexamer-primed cDNA was synthesized using the Superscript III Reverse 
Transcriptase kit (Invitrogen).  Quantitative PCR of hTR was carried out as described(49, 
50), respectively.  For each experiment, the side-by-side comparisons were made on 
simultaneously prepared cDNA. 
Immunoblotting studies.   Immunoblotting was performed as described(49).  Briefly, 
cultured cells were lysed using radioimmunoprecipitation assay (RIPA) buffer 
supplemented with a protease inhibitor cocktail (Roche).  Proteins were resolved with 
SDS-PAGE, and after transfer to a nitrocellulose membrane, were blocked in Odyssey 
blocking buffer (LI-COR).  The following primary antibodies were used: human NAF1 
(rabbit, ab157106, 1:1000; Abcam), Myc (mouse, clone 4A6, 1:1000; Millipore), human 
Dyskerin (rabbit, sc-48794, 1:250; Santa Cruz), and GFP (mouse, 7.1 and 13.1, 1:1000; 
Roche) with loading controls actin (mouse, ab8226, 1:2000; Abcam), tubulin (rabbit, 
ab6046, 1:5000; Abcam), PARP (rabbit, 9542S, 1:1000; Cell Signaling Technology), or 
GAPDH (mouse, mAbcam9498, 1:1000; Abcam).  Secondary antibodies were conjugated 
to dyes IR680 or IR800 (donkey, 1:10,000; LI-COR), and blots were visualized using an 
Odyssey scanner (LI-COR).  Cell fractionation was performed using NE-PER Nuclear 
and Cytoplasmic Extraction Reagents (Thermo Scientific). 
Statistical analyses. Statistical comparisons were made using GraphPad Prism software 
and all P-values are two-sided. Student’s t-test was used for comparison of means and P-




Figure 1. Rare NAF1 variants segregate with short telomere disease phenotypes and low TR 
levels. A. Pedigrees of cases identified in a Johns Hopkins-based Registry (JH1, JH2) with NAF1 
genotypes shown below the individuals sequenced. B. Chromatograms of rare NAF1 variants by 
Sanger sequencing. C. NAF1 variants are absent in public database as well as additional controls 
we sequenced. D. TR levels by qRT-PCR in lymphoblastoid cell lines (LCLs) with pedigree 
identifiers referring to panel A.  TR levels from DKC1 mutation carriers serve as a positive 
control and the DKC1 missense mutations are annotated below.  Means are from 3 separate RNA 
isolations and experiments, and the error bars represent s.e.m.  E and F. Age-adjusted telomere 
length in lymphocytes and granulocytes, respectively, measured by flow cytometry and 
fluorescence in situ hybridization (flowFISH) with pedigree identifiers corresponding to 
individuals in panel A. The nomogram was constructed from 192 healthy controls and the 









Figure 2. Disease-associated NAF1 mutations disturb TR stability.  A. Schema of NAF1 
protein showing its conserved domains and predicted size of the truncated proteins 
(NP_612395.2). B. Western blot of NAF1 and dyskerin in lymphoblastoid cell lines derived from 
unrelated controls and individuals from JH1 family. The ‘+’ refers to NAF1 S329fs heterozygous 
mutation carriers (1.III.1 and I.III.2) and ‘-’ refers to a non-carrier family member (I.IV.1).  
Pedigree identifiers refer to Fig. 1A. C. Western blot for Myc-tagged NAF1 at an isogenic 
doxycycline inducible locus in HeLa cells.  D. Immunoblot of NAF1 in HeLa cells after shRNA 
knockdown (day 8 timepoint).  E and F. TR levels measured by qRT-PCR and northern blot, 
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respectively.  Mean for qRT-PCR result represents 3 independent experiments (P=0.001). G. 
Immunoblot for NAF1 after stable shRNA knockdown in HeLa cells with doxycycline induction 
of Myc-tagged NAF1. H. TR levels measured by qRT-PCR after stable shRNA knockdown (48 
hours post-induction).  Mean shown is from 3 technical replicates.  P-value for sLuc vs. shNAF is 
<0.0001, for shNAF1 vs. shNAF1+WT is 0.0002, and for shNAF1+WT vs. shNAF1+K319fs is 
0.0003.  I. Chromatogram of homozygous c.984insA S329fs disease-associated mutation knocked 
into the endogenous NAF1 locus of HCT116 cells using CRISPR/Cas9.  J. NAF1 immunoblot on 
lysates from CRISPR/Cas9 edited HCT116 cells.  K and L. TR levels quantified by qRT-PCR 
and northern blot, respectively.  For K, mean reflects 4 independent RNA isolations and 









































Figure 3. Mutant NAF1 lacks a C-terminal nuclear localization signal (NLS). A. NAF1 
amino acid alignment within and flanking the NLS for disease-associated mutations and those 
studied for nuclear localization by immunufluorescence are additionally shown.  The four 
conserved lysine residues are indicated by dots above, and the bipartite NLS sequences are 
underlined.  B. Western blot of Myc-tagged NAF1 in the HeLa doxycycline-inducible system 
after 3 hour exposure to Leptomycin B (LMB).  C. Immunufluorescence images showing sub-
cellular localization of Myc-tagged NAF1 (green).  Fluorophores in the three-color overlay are 
labeled to the left.  Images were taken at 63X magnification (scale bar=20 microns).  D. 
Quantification of the NAF1 cytoplasmic fraction represents the intensity of cytoplasmic anti-Myc 
staining (defined by tubulin positive area) relative to the nuclear staining (DAPI area).  
Approximately 100 cells were quantified for each cell line and mean values are shown with error 
bars representing s.e.m. Analysis was performed blinded to genotype.  E. Western blot of total 
(T), cytoplasmic (C) and nuclear (N) protein lysates of parental HCT116 and CRISPR/Cas9 
edited HCT116 cells. For the quantification shown below, the total and cytoplasmic fractions 
were normalized to GAPDH, while the nuclear fraction was normalized to PARP.  ***P<0.001 
(Student’s t-test). 
	   101 
References  
 
1. Xu, J., Murphy, S.L., Kochanek, K.D., and Bastian, B.A. 2016. Deaths: Final 
Data for 2013. Natl Vital Stat Rep 64:1-119. 
2. Stanley, S.E., and Armanios, M. 2015. The short and long telomere syndromes: 
paired paradigms for molecular medicine. Curr Opin Genet Dev 33:1-9. 
3. Stanley, S.E., Chen, J.J., Podlevsky, J.D., Alder, J.K., Hansel, N.N., Mathias, 
R.A., Qi, X., Rafaels, N.M., Wise, R.A., Silverman, E.K., et al. 2015. Telomerase 
mutations in smokers with severe emphysema. J Clin Invest 125:563-570. 
4. Steele, M.P., Speer, M.C., Loyd, J.E., Brown, K.K., Herron, A., Slifer, S.H., 
Burch, L.H., Wahidi, M.M., Phillips, J.A., 3rd, Sporn, T.A., et al. 2005. Clinical 
and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care 
Med 172:1146-1152. 
5. Silverman, E.K., Weiss, S.T., Drazen, J.M., Chapman, H.A., Carey, V., Campbell, 
E.J., Denish, P., Silverman, R.A., Celedon, J.C., Reilly, J.J., et al. 2000. Gender-
related differences in severe, early-onset chronic obstructive pulmonary disease. 
Am J Respir Crit Care Med 162:2152-2158. 
6. Alder, J.K., Chen, J.J., Lancaster, L., Danoff, S., Su, S.C., Cogan, J.D., Vulto, I., 
Xie, M., Qi, X., Tuder, R.M., et al. 2008. Short telomeres are a risk factor for 
idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 105:13051-13056. 
7. Armanios, M. 2012. Telomerase and idiopathic pulmonary fibrosis. Mutat Res 
730:52-58. 
8. Alder, J.K., Guo, N., Kembou, F., Parry, E.M., Anderson, C.J., Gorgy, A.I., 
Walsh, M.F., Sussan, T., Biswal, S., Mitzner, W., et al. 2011. Telomere length is a 
determinant of emphysema susceptibility. Am J Respir Crit Care Med 184:904-
912. 
9. Alder, J.K., Barkauskas, C.E., Limjunyawong, N., Stanley, S.E., Kembou, F., 
Tuder, R.M., Hogan, B.L., Mitzner, W., and Armanios, M. 2015. Telomere 
dysfunction causes alveolar stem cell failure. Proc Natl Acad Sci U S A 112:5099-
5104. 
10. Tsuji, T., Aoshiba, K., and Nagai, A. 2006. Alveolar cell senescence in patients 
with pulmonary emphysema. Am J Respir Crit Care Med 174:886-893. 
11. Cronkhite, J.T., Xing, C., Raghu, G., Chin, K.M., Torres, F., Rosenblatt, R.L., and 
Garcia, C.K. 2008. Telomere shortening in familial and sporadic pulmonary 
fibrosis. Am J Respir Crit Care Med 178:729-737. 
12. Armanios, M. 2009. Syndromes of telomere shortening. Annu Rev Genomics Hum 
Genet 10:45-61. 
13. Alder, J.K., Stanley, S.E., Wagner, C.L., Hamilton, M., Hanumanthu, V.S., and 
Armanios, M. 2015. Exome Sequencing Identifies Mutant TINF2 in a Family 
With Pulmonary Fibrosis. Chest 147:1361-1368. 
14. Parry, E.M., Alder, J.K., Qi, X., Chen, J.J., and Armanios, M. 2011. Syndrome 
complex of bone marrow failure and pulmonary fibrosis predicts germline defects 
in telomerase. Blood 117:5607-5611. 
15. Alder, J.K., Parry, E.M., Yegnasubramanian, S., Wagner, C.L., Lieblich, L.M., 
Auerbach, R., Auerbach, A.D., Wheelan, S.J., and Armanios, M. 2013. Telomere 
	   102 
Phenotypes in Females with Heterozygous Mutations in the Dyskeratosis 
Congenita 1 (DKC1) Gene. Hum Mutat. 
16. Silhan, L.L., Shah, P.D., Chambers, D.C., Snyder, L.D., Riise, G.C., Wagner, 
C.L., Hellstrom-Lindberg, E., Orens, J.B., Mewton, J.F., Danoff, S.K., et al. 2014. 
Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. Eur 
Respir J 44:178-187. 
17. Armanios, M., Chen, J.L., Chang, Y.P., Brodsky, R.A., Hawkins, A., Griffin, 
C.A., Eshleman, J.R., Cohen, A.R., Chakravarti, A., Hamosh, A., et al. 2005. 
Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in 
autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A 
102:15960-15964. 
18. Armanios, M.Y., Chen, J.J., Cogan, J.D., Alder, J.K., Ingersoll, R.G., Markin, C., 
Lawson, W.E., Xie, M., Vulto, I., Phillips, J.A., 3rd, et al. 2007. Telomerase 
mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356:1317-
1326. 
19. Tsakiri, K.D., Cronkhite, J.T., Kuan, P.J., Xing, C., Raghu, G., Weissler, J.C., 
Rosenblatt, R.L., Shay, J.W., and Garcia, C.K. 2007. Adult-onset pulmonary 
fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 104:7552-
7557. 
20. Cogan, J.D., Kropski, J.A., Zhao, M., Mitchell, D.B., Rives, L., Markin, C., 
Garnett, E.T., Montgomery, K.H., Mason, W.R., McKean, D.F., et al. 2015. Rare 
Variants in RTEL1 are Associated with Familial Interstitial Pneumonia. Am J 
Respir Crit Care Med. 
21. Stuart, B.D., Choi, J., Zaidi, S., Xing, C., Holohan, B., Chen, R., Choi, M., 
Dharwadkar, P., Torres, F., Girod, C.E., et al. 2015. Exome sequencing links 
mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere 
shortening. Nat Genet 47:512-517. 
22. Mitchell, J.R., Cheng, J., and Collins, K. 1999. A box H/ACA small nucleolar 
RNA-like domain at the human telomerase RNA 3' end. Mol Cell Biol 19:567-576. 
23. Mitchell, J.R., Wood, E., and Collins, K. 1999. A telomerase component is 
defective in the human disease dyskeratosis congenita. Nature 402:551-555. 
24. Chen, J.L., Blasco, M.A., and Greider, C.W. 2000. Secondary structure of 
vertebrate telomerase RNA. Cell 100:503-514. 
25. Venteicher, A.S., Meng, Z., Mason, P.J., Veenstra, T.D., and Artandi, S.E. 2008. 
Identification of ATPases pontin and reptin as telomerase components essential 
for holoenzyme assembly. Cell 132:945-957. 
26. Egan, E.D., and Collins, K. 2012. Biogenesis of telomerase ribonucleoproteins. 
Rna 18:1747-1759. 
27. Yu, Y.T., and Meier, U.T. 2014. RNA-guided isomerization of uridine to 
pseudouridine--pseudouridylation. RNA Biol 11:1483-1494. 
28. Schmidt, J.C., and Cech, T.R. 2015. Human telomerase: biogenesis, trafficking, 
recruitment, and activation. Genes Dev 29:1095-1105. 
29. Hoareau-Aveilla, C., Bonoli, M., Caizergues-Ferrer, M., and Henry, Y. 2006. 
hNaf1 is required for accumulation of human box H/ACA snoRNPs, scaRNPs, 
and telomerase. RNA 12:832-840. 
	   103 
30. Fatica, A., Dlakic, M., and Tollervey, D. 2002. Naf1 p is a box H/ACA snoRNP 
assembly factor. Rna 8:1502-1514. 
31. Darzacq, X., Kittur, N., Roy, S., Shav-Tal, Y., Singer, R.H., and Meier, U.T. 2006. 
Stepwise RNP assembly at the site of H/ACA RNA transcription in human cells. J 
Cell Biol 173:207-218. 
32. Goldman, F., Bouarich, R., Kulkarni, S., Freeman, S., Du, H.Y., Harrington, L., 
Mason, P.J., Londono-Vallejo, A., and Bessler, M. 2005. The effect of TERC 
haploinsufficiency on the inheritance of telomere length. Proc Natl Acad Sci U S 
A 102:17119-17124. 
33. Hao, L.Y., Armanios, M., Strong, M.A., Karim, B., Feldser, D.M., Huso, D., and 
Greider, C.W. 2005. Short telomeres, even in the presence of telomerase, limit 
tissue renewal capacity. Cell 123:1121-1131. 
34. Alder, J.K., Cogan, J.D., Brown, A.F., Anderson, C.J., Lawson, W.E., Lansdorp, 
P.M., Phillips, J.A., 3rd, Loyd, J.E., Chen, J.J., and Armanios, M. 2011. Ancestral 
mutation in telomerase causes defects in repeat addition processivity and 
manifests as familial pulmonary fibrosis. PLoS genetics 7:e1001352. 
35. Leulliot, N., Godin, K.S., Hoareau-Aveilla, C., Quevillon-Cheruel, S., Varani, G., 
Henry, Y., and Van Tilbeurgh, H. 2007. The box H/ACA RNP assembly factor 
Naf1p contains a domain homologous to Gar1p mediating its interaction with 
Cbf5p. J Mol Biol 371:1338-1353. 
36. Kittur, N., Darzacq, X., Roy, S., Singer, R.H., and Meier, U.T. 2006. Dynamic 
association and localization of human H/ACA RNP proteins. RNA 12:2057-2062. 
37. Vulliamy, T., Marrone, A., Goldman, F., Dearlove, A., Bessler, M., Mason, P.J., 
and Dokal, I. 2001. The RNA component of telomerase is mutated in autosomal 
dominant dyskeratosis congenita. Nature 413:432-435. 
38. Strong, M.A., Vidal-Cardenas, S.L., Karim, B., Yu, H., Guo, N., and Greider, 
C.W. 2011. Phenotypes in mTERT(+)/(-) and mTERT(-)/(-) mice are due to short 
telomeres, not telomere-independent functions of telomerase reverse transcriptase. 
Mol Cell Biol 31:2369-2379. 
39. Zhong, F., Savage, S.A., Shkreli, M., Giri, N., Jessop, L., Myers, T., Chen, R., 
Alter, B.P., and Artandi, S.E. Disruption of telomerase trafficking by TCAB1 
mutation causes dyskeratosis congenita. Genes Dev 25:11-16. 
40. Walne, A.J., Vulliamy, T., Marrone, A., Beswick, R., Kirwan, M., Masunari, Y., 
Al-Qurashi, F.H., Aljurf, M., and Dokal, I. 2007. Genetic heterogeneity in 
autosomal recessive dyskeratosis congenita with one subtype due to mutations in 
the telomerase-associated protein NOP10. Hum Mol Genet 16:1619-1629. 
41. Vulliamy, T., Beswick, R., Kirwan, M., Marrone, A., Digweed, M., Walne, A., 
and Dokal, I. 2008. Mutations in the telomerase component NHP2 cause the 
premature ageing syndrome dyskeratosis congenita. Proc Natl Acad Sci U S A 
105:8073-8078. 
42. Codd, V., Nelson, C.P., Albrecht, E., Mangino, M., Deelen, J., Buxton, J.L., 
Hottenga, J.J., Fischer, K., Esko, T., Surakka, I., et al. 2013. Identification of 
seven loci affecting mean telomere length and their association with disease. Nat 
Genet 45:422-427, 427e421-422. 
	   104 
43. Pooley, K.A., Bojesen, S.E., Weischer, M., Nielsen, S.F., Thompson, D., Amin Al 
Olama, A., Michailidou, K., Tyrer, J.P., Benlloch, S., Brown, J., et al. 2013. A 
genome-wide association scan (GWAS) for mean telomere length within the 
COGS project: identified loci show little association with hormone-related cancer 
risk. Hum Mol Genet 22:5056-5064. 
44. Iles, M.M., Bishop, D.T., Taylor, J.C., Hayward, N.K., Brossard, M., Cust, A.E., 
Dunning, A.M., Lee, J.E., Moses, E.K., Akslen, L.A., et al. 2014. The effect on 
melanoma risk of genes previously associated with telomere length. J Natl Cancer 
Inst 106. 
45. Jonassaint, N.L., Guo, N., Califano, J.A., Montgomery, E.A., and Armanios, M. 
2013. The gastrointestinal manifestations of telomere-mediated disease. Aging 
Cell 12:319-323. 
46. Gorgy, A.I., Jonassaint, N.L., Stanley, S.E., Koteish, A., DeZern, A.E., Walter, 
J.E., Sopha, S.C., Hamilton, J.P., Hoover-Fong, J., Chen, A.R., et al. 2015. 
Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere 
disorders. Chest. 
47. Penno, M.B., Pedrotti-Krueger, M., and Ray, T. 1993. Cyropreservation of whole 
blood and isolated lymphocytes for B-cell immortalization. J. Tiss. Cult. Meth. 
15:43-48. 
48. Baerlocher, G.M., Vulto, I., de Jong, G., and Lansdorp, P.M. 2006. Flow 
cytometry and FISH to measure the average length of telomeres (flow FISH). Nat 
Protoc 1:2365-2376. 
49. Parry, E.M., Alder, J.K., Lee, S.S., Phillips, J.A., 3rd, Loyd, J.E., Duggal, P., and 
Armanios, M. 2011. Decreased dyskerin levels as a mechanism of telomere 
shortening in X-linked dyskeratosis congenita. Journal of medical genetics 
48:327-333. 
50. Vidal-Cardenas, S.L., and Greider, C.W. 2010. Comparing effects of mTR and 
mTERT deletion on gene expression and DNA damage response: a critical 
examination of telomere length maintenance-independent roles of telomerase. 





Supplementary Figure 1. Characteristics of pulmonary fibrosis-emphysema probands case 
studies. A and B. Age-adjusted telomere length in lymphocytes and granulocytes, respectively, of 
5 genetically uncharacterized familial pulmonary fibrosis-emphysema probands with autosomal 
dominant telomere-mediated disease who were studied by whole genome sequencing.  In one 
case there were insufficient events to measure granulocyte telomere length.  Percentiles are 
shown based on data from 192 healthy controls. C. Clinical features of five probands studied by 
genome sequencing. Proband #4 is the index JH1 case. NCPH refers to non-cirrhotic portal 
hypertension.  D. TR levels in the five probands measured by qRT-PCR in lymphoblastoid cell 
lines (LCLs) and stratified relative to controls (n=6).  TR levels from DKC1 mutation carriers 
(T49S and R158W) are included as a positive control.  Means represent data from three 














Supplementary Figure 2. Detailed clinical history of short telomere syndrome features in 
NAF1 mutation carriers. The respective genotypes are shown in Figure 1A. 
Supplementary Figure 3. Full-length NAF1 cDNA resuces TR levels in homozygous mutant 
HCT116 cells.  A. NAF1 immunoblot on lysates derived from NAF1S329fs/S329fs  cells that were 
transduced with GFP- or NAF1- containing lentiviral vectors.  Parental HCT116 (NAF1WT/WT) 
cells were also transduced with GFP as a control.  B. TR levels measured by qRT-PCR with 
calculations based on 3 independent RNA isolations.  C. Northern blot for TR with quantification 
shown below.  TR levels were measured 10 days after lentiviral transduction.  Data are expressed 
as mean ± s.e.m. *P<0.05 and ***P<0.001 (Student’s t-test). 
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Supplementary Figure 4. Multi-species NAF1 alignment showing conserved motifs.  Multi-
species alignment of human NAF1 protein alongside representative vertebrate, invertebrate, 
fungal and plant species shows conserved sequences.  The black shading indicates a minimum of 
50% identity and grey shading 50% similarity.  Conserved motifs and domains, including the 
nuclear localization signal (NLS), are denoted above the protein alignment.  Alpha helices are 
colored in blue, beta-sheets are in red, and random coil in grey.  The position of the two disease-
associated frameshift mutations is denoted by arrows. 
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Supplementary Figure 5. Leptomycin B (LMB) blocks nuclear export and TR levels after 
nuclear localization is restored for NAF1K319fs.  A. LMB blocks export of NAF1 in HeLa cells.  
The grayscale panels show Myc-tagged wild-type NAF1 accumulates in the nucleus after a 3 hour 
exposure of LMB.  Cytoplasmic and nuclear areas are defined by tubulin (red) and DAPI (blue) 
staining.  Scale bar is 20 microns.  B. Immunoblot for NAF1 in isogenic HeLa cells after shRNA 
knockdown and 48 hours after doxycycline induction.  C. qRT-PCR of TR in the same 
experiment shown in B and means are from 3 technical replicates.  All results shown here were 
replicated 3 times.  Error bars represent s.e.m. and **P<0.01 (Student’s t-test). 
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